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Abstract
Hepatocarcinoma (HCC) is a highly prevalent cancer 
worldwide and its inflammatory background was esta-
blished long ago. Recent studies have shown that innate 
immunity is closely related to the HCC carcinogenesis. 
An effective innate immunity response relies on the toll-
like receptors (TLR) found in several different liver cells 
which, through different ligands and many signaling 
pathways can elicit, not only a pro-inflammatory but also 
an oncogenic or anti-oncogenic response. Our aim was 
to study the role of TLRs in the liver oncogenesis and 
as a consequence their value as potential therapeutic 
targets. We performed a systematic review of PubMed 
searching for original articles studying the relationship 
between HCC and TLRs until March 2015. TLR2 appears 
to be a fundamental stress-sensor as its absence re-
veals an augmented tendency to accumulate DNA-
damages and to cell survival. However, pathways are 
still not fully understood as TLR2 up-regulation was also 
associated to enhanced tumorigenesis. TLR3 has a well-
known protective role influencing crucial processes like 
angiogenesis, cell growth or proliferation. TLR4 works 
as an interesting epithelial-mesenchymal transition’s 
inducer and a promoter of cell survival probably induc-
ing HCC carcinogenesis even though an anti-cancer role 
has already been observed. TLR9’s influence on carcino-
genesis is also controversial and despite a potential anti-
cancer capacity, a pro-tumorigenic role is more likely. 
Genetic polymorphisms in some TLRs have been found 
and its influence on the risk of HCC has been reported. 
As therapeutic targets, TLRs are already in use and 
have a great potential. In conclusion, TLRs have been 
shown to be an interesting influence on the HCC’s micro-
environment, with TLR3 clearly determining an anti-
tumour influence. TLR4 and TLR9 are considered to have 
a positive relationship with tumour development even 
though, in each of them anti-tumorigenic signals have 
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been described. TLR2 presents a more ambiguous role, 
possibly depending on the stage of the inflammation-
HCC axis. 
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Core tip: The importance of hepatocarcinoma (HCC) is 
undeniable in the current medical perspective. However, 
a lot still remains to be understood in this context. 
Therefore, this review aims to present the significance 
of innate immunity in HCC through toll-like receptors as 
they have already shown interesting effects on tumour’s
microenvironment, influencing its progression or regre-
ssion. As a result we also render some therapeutic 
usages of the established knowledge in this area. 
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oncogenesis? World J Hepatol 2016; 8(3): 162-182  Available 
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INTRODUCTION
Liver cancer is one of the most common cancers 
worldwide, with hepatocarcinoma (HCC) being, by far, 
the most frequent type[1,2].
Due to its close contact with gut, via portal vein, liver 
faces a continuous exposure to gut-derived bacterial 
products, toxics and many other agents[3]. In the 
presence of such pathogens or irritants and associated 
molecules our body is able to respond in a manner 
that aims to prevent injury and combat infection. This 
protection system is called inflammation which, despite 
its tremendous defensive and antiviral/antibacterial 
importance in the short term, starts to become dele-
terious when prolonged or exaggerated - chronic inflam-
mation - possibly leading to fibrosis, cirrhosis and, 
ultimately, HCC[4]. 
Therefore, the idea that hepatic carcinogenesis 
arouses from an inflammatory basis is not new. Several 
studies already focused on the development of HCC and 
possibilities like the c-Myc elevation or the deregulated 
SRY and SGF29 pathways have been proposed[5]. 
However, just in the last few years we have become 
aware of the critical role of innate immunity in chronic 
liver diseases, including HCC[6,7].
Toll-like receptors (TLRs) are a family of pattern-
recognition receptors (PRRs) that can be activated 
by either pathogen-associated molecular patterns 
(PAMPs) or danger/damage-associated molecular 
patterns (DAMPs), with their own importance in eliciting 
innate immunity, regulation of inflammation and tissue 
regeneration. To date, 11 human TLRs have been 
identified[8]. In recent years, activation of several TLRs 
have been associated with viral hepatitis, steatohepatitis 
(alcoholic or non-alcoholic) and to the progression of the 
inflammation-fibrosis-HCC axis[9-11]. However, data is 
somewhat contradictory and no clear conclusions have 
been made.
In this line of thoughts, this review aims to present 
an overview of the expression of TLRs in the liver, its 
influence on the development of liver carcinogenesis as 
chronic inflammatory inducers or potential oncogenes 
as well as possible therapeutic targets.
RESEARCH
Specific criteria were defined in order to guide this 
systematic review. Firstly, a query to obtain the articles 
related to the theme on PubMed was built: [(Hepato-
carcinoma) OR (Hepatocarcinogenesis) OR (hepatic 
cancer) OR (hepatocellular carcinoma) OR (liver cancer)] 
AND [(toll like receptors) OR (toll like receptor)]. With 
this query we intended to embrace a wide range of 
articles until March 2015, which then would be carefully 
selected. 
A total amount of 277 articles were obtained through 
the referred search. After discarding the duplicates and 
adding 28 articles obtained through cross-referencing, 
305 articles were available to be screened. The following 
inclusion criteria were used: (1) studies that were pub-
lished until the end March 2015; (2) the article should 
be written in English; and (3) studies relevant to the 
theme (presenting original data). As exclusion criteria 
we defined: (1) studies considered by the authors as 
unrelated to the theme; and (2) non-original studies. 
These criteria were applied by reading the title and 
abstract resulting in 227 articles excluded. After this 
step, the remaining 78 studies were selected for full-text 
reading. On a second level of eligibility, 18 more studies 
were excluded and 60 studies were selected, analysed 
and included in this revision (Figure 1). 
Data about the defined topics were obtained from 
each article (Table 1) and the information was then 
summed up and organized in the present systematic 
review according to: The TLRs’ expression in each liver 
cell; separately role of TLR2, TLR3, TLR4 and TLR9 in 
inflammatory-driven hepatocarcinoma; known TLRs’ 
polymorphisms/genetic variations that influence the 
risk of hepatocarcinoma and lastly, TLRs modulators 
possibly used in hepatocarcinoma’s therapeutics.
TLR EXPRESSION IN HEPATIC CELL 
POPULATION
The liver is a very special organ when it comes to 
dealing with pathogens. Due to its vascular links, contact 
with gut-derived bacteria is constant and, therefore, 
mechanisms not only to defend the organism from 
these pathogens but also to tolerate them, had to be 
163 January 28, 2016|Volume 8|Issue 3|WJH|www.wjgnet.com
Lopes JAG et al . Hepatocarcinoma and toll-like receptors
developed[8]. In this duality, TLRs play an interesting 
role as it is known that, in a healthy liver, mRNA levels 
of TLRs like TLR1, 2, 4, 6, 7, 8, 9 and 10 are decreased 
when compared to other organs[9]. 
In the liver, hepatocytes represent 60%-80% of 
the total cell population. Here, it can be found mRNA 
from all TLRs; however, only a response from TLR2 and 
TLR4, to their ligands, can be obtained[12]. Interestingly, 
only the response of TLR2 is up-regulated under inflam-
matory conditions[13]. 
Besides hepatocytes, it is possible to find, in the 
liver, non-parenchymal cells which consist of Kupffer 
cells (KCs), dendritic cells (DCs), Lymphocytes, hepatic 
stellate cells (HSCs) and liver sinusoidal endothelial cells 
(LSECs).
KCs not only express lipopolysaccharide (LPS)-
responsive TLR4 but also TLR2, TLR3 and TLR9 that 
respond to their ligands[14]. These cells develop an 
inflammatory response to high levels of LPS but produce 
an anti-inflammatory cytokine (IL-10) in response to 
continuous low levels of LPS, known as LPS tolerance[15]. 
DCs represent a small population (< 1%). In humans, 
the plasmocytoid DCs subset expresses TLR1, TLR7 
and TLR9 while other subsets carry all TLRs with the 
exception of TLR9[16]. When it comes to Lymphocytes 
population and TLRs relationship it is important to notice 
that differences can be found from one subpopulation 
to another. Natural killer (NK) cells contain TLR1, TLR2, 
TLR3, TLR4, TLR6, TLR7, TLR8 and TLR9[1,17] but T 
cells are only activated through TLR2 while B cells 
rely on TLR2, TLR4, TLR7 and TLR9[18]. HSCs, also in 
small proportion (< 1%), when activated are able to 
express TLR4 responsive to LPS which, in turn, enables 
inflammatory cytokines’ secretion[19]. LSECs express 
mRNA from TLR1 to TLR9 despite not being able to 
respond to TLR5 ligands[20]. 
IMPORTANCE OF TLRS IN 
INFLAMMATORY-INDUCED HCC
HCC has long been considered a chronic-inflammation 
driven cancer independently of the possible risk factors; 
virus induced hepatitis, smoke, alcohol or metabolic 
diseases. Despite that, the liver is an organ with seve-
ral mechanisms readily available to defend against 
carcinogenesis. Among these, we found PRRs, with 
special attention to TLRs which were already shown to 
exhibit different roles in the regulation of tumorigenesis 
and tumour progression. To date several works have 
documented its influence not only in specific types of 
cancer - breast, ovarian, prostate and lung - but also 
in processes directly linked with cancer - resistance to 
apoptosis, increased invasiveness and metastasis. This 
is the reflection of their actions on metalloproteases and 
integrins, tumour cell immune escape, among others[21-23]. 
However, the cellular and molecular effectors mediating 
the interplay between TLRs and HCC are still largely 
unknown. 
TLR2 
When the TLR2 signal is triggered, the downstream 
cascade initiates through a “Myd88 dependent pathway” 
with the activation of the apoptosis signal regulating 
kinase 1 (ASK1)/p38 mitogen-activated protein kinase 
(p38 MAPK)/nuclear factor kappa B (NF-κB), or through 
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Articles identified through 
database searching (n  = 277)
Articles obtained through 
cross-referencing (n  = 28)
Rejected articles using 
exclusion criteria (n  = 227)
Articles screened 
(n  = 305)
Exclusion criteria 
   Not written in English
   Unrelated to the theme
   Non-original studies
Exclusion criteria 
   Unrelated to the theme
Rejected articles using 
exclusion criteria (n  = 18)
Full text articles assessed 
for eligibility (n  = 78)
Articles include in the 
qualitative synthesis (n  = 60)
Articles obtained after duplicates removal (n  = 305)
Figure 1  Methods’ flowchart. A total amount of 277 articles were obtained, on PubMed, through the query [(hepatocarcinoma) OR (hepatocarcinogenesis) OR (hepatic 
cancer) OR (hepatocellular carcinoma) OR (liver cancer)] AND [(toll like receptors) OR (toll like receptor)]. After discarding the duplicates and adding 28 articles 
obtained through cross-referencing, 305 articles were available to be screened. The following inclusion criteria were used: (1) studies that were published until the end 
March 2015; (2) the article should be written in English; and (3) studies relevant to the theme (presenting original data). As exclusion criteria we defined: (1) studies 
considered by the authors as unrelated to the theme; and (2) non-original studies. These criteria were applied by reading the title and abstract resulting in 227 articles 
excluded. After this step, the remaining 78 studies were selected for full-text reading. On a second level of eligibility, 18 more studies were excluded and 60 studies 
were selected, analysed and included in this revision. 
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Ref. Year Type of study Methods Limitations Conclusions
Chew et al[1] 2012 
December
Experimental Natural killer cell activation and 
cytotoxicity were assessed in vitro 
after treatment with the TLR3 
ligand poly (I:C). The effect of TLR 
in a spontaneous liver tumor mouse 
model and a transplanted tumor 
mouse model were determined by 
Immunohistochemistry and PCR
The effect of poly (I:C) on tumor 
growth was only analyzed in 
a transplanted, nonorthotopic 
model of HCC. The effect of 
poly (I:C) on human NK cells 
was assessed only with cells 
from healthy donors. Not 
all HCC cell lines undergo 
apoptosis after TLR3 triggering 
and the reason is not known
TLR3 is an important 
modulator of HCC 
progression and is a 
potential target for novel 
immunotherapy
Mohamed et al[2] 2015 March Experimental Tissue microarrays containing 
liver samples from patients with 
cirrhosis, viral hepatitis and HCC 
were examined for expression of 
TLR7 and TLR9. Proliferation of 
human HCC cell lines was studied 
following stimulation of TLR7 and 
TLR9 using agonists (imiquimod 
and CpG-ODN respectively) and 
inhibition with a specific antagonist 
(IRS-954) or chloroquine. The 
effect of these interventions was 
confirmed in a xenograft model 
and DEN/NMOR-induced model 
of HCC
Before translation to the 
clinical arena, it is important to 
further characterize the exact 
mechanisms through which 
TLR7 and TLR9 exert their 
actions and determine what 
effects their inhibition may 
have on the immune system
Inhibiting TLR7 and TLR9 
with IRS-954 or chloroquine 
could potentially be used 
as a novel therapeutic 
approach for preventing 
HCC development and/or 
progression in susceptible 
patients
Dapito et al[3] 2012 April Experimental TLR2-deficient mice, TLR4-
deficient mice, TNFR1-/IL-1R1-
double deficient and C57Bl/6 mice 
were used. HCC was induced by 
intraperitoneal injection of DEN. 
Gut-sterilization was done using a 
combination of ampicillin (1 g/L), 
neomycin (1 g/L), metronidazole (1 
g/L) and vancomycin (500 mg/L) 
in drinking water. Samples from 
patients with features of alcoholic 
hepatitis were used. Liver biopsies 
were obtained from mice and from 
cadaveric donners or resection of 
liver metastases
Clinically feasible methods 
of targeting the intestinal 
microbiota or TLR4 need to 
be established. The quadruple 
combination of antibiotics 
employed is not suitable for 
long-term treatment due to 
known side effects in patients 
with advanced liver disease
Gut sterilization 
restricted to late stages 
of hepatocarcinogenesis 
reduced HCC, suggesting 
that the intestinal microbiota 
and TLR4 represent 
therapeutic targets for HCC 
prevention in advanced liver 
disease
Eiró et al[8] 2014 July Experimental The expression levels of TLR3, 
TLR4 and TLR9 were analyzed 
from 30 patients with HCC 
and correlated with various 
clinicopathological findings and 
with overall survival
In the scoring system, after 
immunostaining analysis, 
when setting of the threshold 
for positive staining and the 
determination of the intensity 
different observers can set 
different thresholds and 
intensity levels
An association between 
TLR3, TLR4 and TLR9 
expression and tumor 
aggressiveness and poor 
prognosis in HCC has been 
observed
Liu et al[12] 2002 July Experimental Cultures of primary mouse 
hepatocytes were incubated with 
LPS to assess its effects on the 
global gene expression, hepatic 
transcription factors, and MAP 
kinase activation
Using hepatocytes' cell lines 
loses the capacity to observe the 
importance of a direct response 
to LPS by hepatocytes
NF-κB activation was 
reduced in TLR4-mutant or 
- null hepatocytes compared 
to control hepatocytes
Matsumura et al[13] 2000 
October
Experimental PCR analysis of mice's hepatocytes 
and an murine hepatoma cell line 
Hepa 1-6
Murine hepatoma cell line 
Hepa 1-6 may have reached 
an overquantitative level after 
stimulation
LPS and proin-flammatory 
cytokines differentially 
regulate gene expression of 
TLR2 and TLR4 in murine 
hepatocytes, which may 
lead to pathologic and host 
defense reactions in the liver
Thobe et al[14] 2007 March Experimental Wester blotting and cytokine 
analysis in a cell culture. Evaluation 
of Kupfer cells response after a 
trauma-hemorrage procedure
Does not explain if the increase 
in MAPK-activity is due to 
TLRs' overexpression
Kupffer cell TLR signaling 
employs different MAPK 
pathways in eliciting 
cytokine and chemokine 
responses following trauma-
hemorrhage
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Knolle et al[15] 1995 
February
Experimental Human Kupffer cells were isolated 
by collagenase perfusion followed 
by centrifugal elutriation and 
analyzed for cytokine secretion 
after 3 d in culture
Only IL-10 and IL-6 were 
analysed
The important role for 
IL-10 in the regulation of 
the local immune response 
in the liver sinusoid after 
Kupffer cells exposure to to 
lipopolysaccharide
Edwards et al[16] 2003 April Experimental Splenocyte reparations were 
enriched for D11c+ and for Ly6C+ 
cells using magnetic selection. Four 
populations were routinely isolated 
and TLR's mRNA was amplified 
by PCR
To analyze the functional 
significance of TLR mRNA 
expression in DCs subsets it 
was only used ligands for TLR7 
and TLR9
mRNA for most TLRs is 
expressed at similar levels 
by murine splenic DC sub-
types. TLR expression 
between plasmacytoid and 
non-plasmacytoid DC is not 
conserved between species
Sawaki et al[17] 2007 March Experimental Total RNA was extracted, and 
mRNA for TLR1, 2, 3, 4, 5, 6, 7, 
9 and b-actin was determined 
by reverse transcription-PCR. 
Nuclear localization of NF-κB was 
determined and cytokines and 
chemokines were measured by a 
commercially available kit
It was not evaluated precise 
roles of NK cell responses in 
vivo
Upon microbial infection, 
macrophages produce IL-12 
that renders NK cells highly 
responsive to TLR agonists 
to produce IFN-γ and 
chemokines, which might 
in turn recruit and fully 
activate macrophages
Meyer-Bahlburg et al[18] 2007 
December
Experimental It was compared the TLR response 
profile of germinal center after 
immunization vs naive mature B 
cell subsets, using real time PCR, 
ELISA and Western Blotting to 
evaluate MyD88 pathway
TLRs' role in B-cells immune 
response was only accessed in 
splenic B cells from MyD88 WT, 
Het, or KO, being studied only 
the MyD88-dependent pathway
B cell-intrinsic TLR signals 
are not required for antibody 
production or maintenance
Paik et al[19] 2003 May Experimental LPS-associated signalling 
molecules in culture-activated 
HSCs and HSCs isolated 
from patients with hepatitis 
C virus-induced cirrhosis was 
evaluated by NF-κB-dependent 
luciferase reporter gene assays, 
electrophoretic mobility shift 
assays and in vitro kinase assays
It does not fully explain why 
only full activated HSCs 
respond to LPS. It was not 
evaluated the activation of 
TLR4 downstream molecules 
like MyD88
Human activated HSCs 
utilize components of TLR4 
signal transduction cascade 
to stimulate NF-ĸB and JNK 
and up-regulate chemokines 
and adhesion molecules
Wu et al[20] 2010 March Experimental Isolated Kupffer cell and liver 
sinusoidal endothelial cells from 
wild-type C57BL/6 mice and 
examined their responses to TLR1 
to TLR9 agonists. Characterization 
of cell surface protein expression 
was done by flow cytometry and 
quantification of mRNA was 
done by reverse transcription-
polymerase chain reaction
The in vitro assay does not 
explore the organ-specific 
regulation of immune 
responses. For the identification 
of TLR-induced antiviral 
cytokine(s) only TLR3 and 
TLR4 were used
Non-parenchymal cells 
display a restricted TLR-
mediated activation 
profile when compared 
with "classical" antigen-
presenting cells which may, 
at least in part, explain their 
tolerogenic function in the 
liver
Huang et al[21] 2012 July Experimental TLR expression in BLE-7402 
cells was assayed by RT-PCR, 
real-time PCR and FCM. To 
investigate the function of TLR2 in 
hepatocarcinoma growth, BLE-7402 
cells were transfected with 
recombinant plasmids expressing 
one TLR2 siRNA
Only the effect on tumour 
volume is evaluated after 
tumour implantation in nude 
mice
TLR2 knockdown inhibit 
proliferation of cultured 
hepatocarcinoma cells and 
decrease the secretion of 
cytokines
Kim et al[22] 2009 
January
Experimental LLC cells were implanted in mice. 
Metastasis enhancing factors were 
identified on a QSTAR XL qQTOF 
mass spectrometer. Gene and 
protein expression were monitored 
by Q-PCR and immunoblot 
analysis. Tumors were analyzed 
by immunohistochemistry and 
indirect immunofluorescence
It does not explain if the 
interaction between versican 
and TLR2 is direct or depends 
on a versican’s ligand
By activating TLR2:TLR6 
complexes and inducing 
TNF-α secretion by myeloid 
cells, versican strongly 
enhances lewis lung 
carcinoma metastatic growth
Lin et al[24] 2013 
January
Experimental A DEN injection was done in 
TLR2-/- and WT mice. Than they 
were sham-treated or treated 
with interferon-gamma. TUNEL, 
heterochromatin and SA b-gal 
staining were performed
The mechanism by which TLR2 
signaling participates in the 
regulation of cellular senescence 
to maintain growth arrest and 
promote programmed cell 
death remains inconclusive
Loss of immune networks 
may play a role in the failure 
of initiating and maintaining 
cellular senescence and 
autophagy flux in the TLR2-
mutant liver tissue
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Lin et al[25] 2013 
October
Experimental WT mice were pre-treated with 
anti-TLR2 antibody and a subset 
of TLR2-/- mice were pre-treatment 
with NAC (antioxidant) or 
physiological saline. Both were 
submitted to DEN. Histology was 
submitted to western blotting, ROS 
assay, immunohistochemistry and 
immunofluorescence
It does not report any results 
about the effects on non-
parenchymal cells like Kuppfer 
cells. It does not reveal 
interactions that regulate the 
signal from TLR2 activation to 
suppression of oxidant and ER 
stressors in HCC
A TLR2 activity defends 
against hepatocarcinogenesis 
through diminishing the 
accumulation of ROS and 
alleviating ER stress and 
unfold protein response
Li et al[26] 2015 March Experimental WT and Tlr2-/- mice were used. 
Flow cytometry, Histopathological 
analysis and Immunofluorescence, 
Western blot and ELISA were 
performed. MDSC induction 
in vitro and functional T cell 
suppression assay and knockdown 
of IL-18 and caspase-8 in 
hepatocytes with quantitative PCR 
were also done
The exact role of IL-18 in MDSC 
generation is still unknown. 
It does not reveal the levels 
of TLR2 that determine the 
possible use of IL-18 as a 
therapeutic target
TLR2 deficiency 
accelerates IL-18-mediated 
immunosuppression 
during liver carcinogenesis, 
providing new insights into 
immune control that may 
assist the design of effective 
immunotherapies to treat 
HCC
Soares et al[27] 2012 
October
Analytic - 
cross sectional
It was used samples from patients 
with hepatitis, cirrhosis and 
hepatocarcinoma. mRNA isolation 
and quantification of TLR2, TLR4, 
NF-κB, TNF-α and COX-2 were 
performed. Immunohistochemical 
evaluation of TLR2 and TLR4 was 
also done
Most patients included in 
the reference group have 
evidence of NAFLD and it was 
demonstrated that NAFLD 
is associated with increased 
hepatic TLR2 and TLR4-mRNA 
expression. the hepatitis, 
cirrhosis and hepatocarcinoma 
groups included both patients 
with HBV infection or HCV 
infection. Included only 
patients with virus-induced 
chronic hepatitis. The method 
used for quantification of 
protein expression was semi-
quantitative
Increased expression 
of TLR2 and TLR4 in 
hepatitis and cirrhosis and 
maintained expression 
in hepatocarcinoma. Up-
regulation of TLR2, TLR4 
and their pro-inflammatory 
mediators is associated with 
virus-induced hepatic IFC 
sequence
Dolado et al[31] 2007 
February
Experimental WT and p38a-/- were used. Growth 
in soft agar was evaluated. 
Intracellular ROS levels were 
determined, immunoblot Analysis 
was performed. To induce p38 
MAPK activation, cells were 
treated with H2O2, sorbitol and 
cisplatin
The tumorigenesis enhanced 
by ROS is not evaluated on 
hepatocarcinoma
Oxidative stress sensing 
plays a key role in the 
inhibition of tumor initiation 
by p38alpha
Kang et al[32] 2011 
November
Experimental For transposon-mediated intra-
hepatic gene transfer mice received 
a transposon- to transposase 
encoding vector (30 mg total 
DNA). DNA was administered by 
hydrodynamic tail vein injection. 
Immunohistochemical analyses 
were performed
It was not investigated if factors 
secreted from pre-malignant 
senescent hepatocytes also 
contribute to the oncogenic 
transformation of neighbouring 
cells
Indicates that senescence 
surveillance represents 
an important extrinsic 
component of the senescence 
anti-tumour barrier, and 
illustrates how the cellular 
senescence program is 
involved in tumour immune 
surveillance
Ogata et al[34] 2006 
December
Experimental Electron microscopic analysis was 
performed using neuroblastoma 
SK-N-SH cells exposed to ER 
stressors. GFP-LC3 fluorescence 
was used to monitor autophagy 
in cells transiently transfected 
with an expression vector for 
GFP-LC3. Then was performed 
an Amino acid uptake assay and 
autophagosome formation was 
evaluated
A signalling pathway other 
than the IRE1-JNK pathway 
may also play important roles 
in the activation of autophagy 
signalling after ER stress. The 
detailed signalling pathway 
for activation of the autophagy 
induced by ER stress is still 
unknown
Disturbance of autophagy 
rendered cells vulnerable to 
ER stress, suggesting that 
autophagy plays important 
roles in cell survival after ER 
stress
Pikarsky et al[36] 2004 
September
Experimental The possibility that NF-κB 
activation is involved in Mdr2-
knockout hepatocarcinogenesis 
was investigated by RelA (p65) 
immunostaining. Hystological 
analysis was performed. To study 
the relationship between the 
It does not explain how the 
inflammatory process in Mdr2-
knockout mice is maintained 
in the double mutants as it is 
independent of hepatocyte NF-
κB activity
NF-κB is essential for 
promoting inflammation-
associated cancer, and is 
therefore a potential target 
for cancer prevention in 
chronic inflammatory 
diseases
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TNF-α-producing cells and NF-
κB activation in the hepatocytes, 
liver sections were stained for both 
TNF-α and p65
Gong et al[37] 2013 
September
Experimental BALB/c mice were used 
and inoculated with H22 
hepatocarcinoma cells into the hind 
thigh muscle. They were treated 
with TLR2/4 ligands, HSP70 and 
HMGB1. The main tumor nodules 
were measured and satellite tumor 
nodes counted. To downregulate 
HMGB1, RAGE or Beclin-1 in 
tumor cells, cells were transduced 
with short interfering RNA
It does not explain the 
mechanisms responsible by the 
NF-κB's phosphorylation in the 
first 30 min. It was observed 
only one of the pathways 
responsible for the involvement 
of HMGB1/RAGE in the NF-κB 
signaling
Activation of NF-κB was 
indispensable for the effect 
of HSP70. HSP70 induced 
a positive feedback loop 
involving Beclin-1/HMGB1 
production, causing re-
phosphorylation of NF-κB
Shi et al[38] 2014 
October
Experimental Human hepatocellular carcinoma 
cell lines were used. Into the cell 
lines were transfected small-
interfeering-RNAs and at 48 
h after transfection, the TLR2-
siRNA-transfected group, scramble 
control group, and blank group 
were treated with recombinant-
HMGB1. Evaluation included 
real time PCR, Western blot, MTT 
assay, Transwell assay and Flow 
cytometry assay
It does not explore the signaling 
pathway that regulates NF-
κB through TLR2 inhibition or 
stimulation with recombinant-
HMGB1
TLR2-siRNA could 
effectively inhibit the 
growth, migration, invasion, 
and expression of NF-κB/
P65, and HMGB1 promoted 
HCC progression via TLR2
Wu et al[39] 2012 April Experimental It was used mice and HCC cell 
lines. Eukaryotic expression 
vectors psTLR2 and psTLR4 were 
created. An adhesion assay, a 
tumor cell proliferation assay, 
a flow cytometric analysis, an 
apoptosis analysis, an analysis 
of gene expression by RT-PCR 
and a western blot analysis were 
performed
More than one signaling 
pathways activated by 
HSPA1A might be required 
for the survival of tumor cells. 
The effect of eHSPA1A was 
only evaluated in one cell 
line. Injection of HSPA1A 
suppressed tumor growth 
in early stage of tumor 
development, but promoted 
tumor growth in later stage
Extracellular HSPA1A 
functions as endogenous 
ligand for TLR2 and TLR4 to 
facilitate tumor growth
Yoneda et al[41] 2008 
November
Experimental HCC cell lines and 74 HCC 
samples were used. Poly 
(I:C), cycloheximide and 
actinomycin were included in 
the study. Profiling analysis 
of TLRs recognized by viral 
components, flow cytometric 
analysis, immunohistochemical 
staining, Detection of TLR3 by 
immunofluorescence, Detection of 
cell viability and apoptosis assays, 
Detection of apoptosis-related 
proteins by immunoblotting, 
NF-κB activity assays and 
measurement of IFN-β were also 
performed
Further evaluation of the 
possible roles and the type 
of regulation associated with 
TLR3 needs to be undertaken
Intracellular TLR3 signalling 
is involved in cell death, 
while in contrast, the cell 
surface TLR3 signalling is 
responsible for activation of 
NF-κB
Zorde-Khvalevsky et al[42] 2009 July Experimental It was used TLR3-WT mice and 
TLR3-/- mice. Partial hepatectomy 
was done followed by 
immuonhistochemistry stainings, 
plasma aminotransferase activity 
assay, measurements of serum 
cytokine levels, semi-quantitative 
reverse-transcription polymerase 
chain reaction, Western blotting, 
caspase-8 immunopurification and 
injection with poly (I:C) or saline 
solution
It is not explained what 
happens to the levels of ALT 
in mice's serum before the 
10-h time point following 70% 
PHx. Cytokine evaluation only 
includes IL-6 and IL-22
TLR3 plays an inhibitory 
role in the priming of 
liver regeneration, thus 
reinforcing the role of the 
innate immune system in 
balancing tissue regeneration
Khvalevsky et al[44] 2007 April Experimental Various cell lines and plasmids 
pTLR7, pTLR8, and pTLR9, 
carrying the respective human TLR 
gene, were used. Transfection 
The role of TLR3 signaling in 
normal hepatocytes requires 
further investigation in vivo. It 
is not specified the degree of 
Preferential induction of the 
apoptotic pathway over the 
cytokine induction pathway 
by TLR3 signaling in
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assays, RNA quantification, 
immuno-staining and flow 
cytometry, were performed
 NF-κB activation obtained 
from the overexpression of 
TLR3 nor the degree of this 
overexpression that is needed
 hepatocellular carcinoma 
cells with potential 
implications for therapeutic 
strategies
Chen et al[45] 2012 July Experimental The human HCC cell line 
HepG2.2.15 was used. After 
treating HepG2.2.15 with BM-06 
or poly (I:C), NF-κB activity was 
checked by dual luciferase reporter 
gene kit. Then it was performed a 
nuclear and cytoplasmic extraction, 
Western blot analysis, a cell 
proliferation assay, cell invasion 
assays and flow-cytometry was 
used to determine the apoptotic 
rate
The role of TLR3 in the 
antiviral defense against HBV 
was not analyzed according 
to differences in the type of 
viruses, the type of cells that 
are infected, the viral load, its 
model of infection (endoplasmic 
 cytoplasmic), and stage of 
infection
BM-06 inhibited the 
proliferation, invasion 
and secretion of HBV, 
and induced apoptosis in 
HepG2.2.15 cells. In addition, 
the antitumor effects of 
BM-06 were superior to poly 
(I:C)
Guo et al[46] 2012 
February
Experimental Cell cultures were used and 
submitted to BM-06 and poly (I:
C) treatment. RNA isolation and 
one-step quantitative real-time 
PCR were performed. Analysis 
included detection of TLR3 by 
immunocytochemistry, luciferase 
reporter assays, Endothelial cell 
tube formation assay, rat aortic 
ring assay, annexin V/PI for 
cell apoptotic analysis and Cell 
migration assays
It does not evaluate the 
molecular mechanisms after 
TLR3 stimulation that lead to 
modulation of endothelial tube-
forming activity of HUVECs 
and vascular sprouting or 
enhanced apoptosis
TLR3 agonists not only affect 
tumor microenvironment by 
suppressing angiogenesis 
but also directly induce 
tumor cell apoptosis and 
inhibit tumor cell migration
Bergé et al[47] 2010 
December
Experimental It was injected transgenic mice 
developing HCC with either 
control siRNAs or siRNA 
targeting neuropilin-1. The 
study used antibodies (goat anti-
TLR3 and rabbit anti-tubulin 
antibody), Western Blotting, and 
Immunofluorescence Analysis. 
Real-time RT-PCR, ELISA, MTT 
assay and three-dimensional 
collagen assay were also performed
It is not known why INF-γ does 
not inhibit cells' functions in 
the in vitro study despite the 
high levels in HCC. In vivo 
evaluation was not performed
Synthetic siRNAs inhibit 
target-independently HCC 
growth and angiogenesis 
through the activation of the 
innate interferon response 
and by directly inhibiting 
endothelial cell function
Xu et al[48] 2013 
October
Experimental Thirty rats were used, all 30 were 
fed with 2-acetylaminofluorene 
to establish the HCC model. Two 
animal groups were treated, 
respectively, with the drug 
candidate (BM-06) and poly (I:C). It 
was performed a H and E staining, 
an Immunohistochemical staining, 
a Western blot analysis
It does not explore the pathway 
though which BM-06 and poly 
(I:C) are capable of inducing cell 
death. It is not evaluated TLR3's 
downstream molecules to 
explain the signalling pathway 
responsible for these results
Treatment with BM-06, 
showed a decrease in tumor 
growth and cell proliferation, 
and an increase in apoptosis 
compared with that in a 
phosphate-buffered saline 
control group
Wang et al[49] 2013 
August
Experimental Fifty-three HCC and ten normal 
liver specimens were analyzed by 
immunohistochemistry, and three 
cell lines were used for in vitro 
studies. Lipopolysaccharide was 
used to activate TLR4 signaling. 
Cell survival, proliferation and 
invasion were examined
Only a specific amount of LPS 
has shown to have an effect on 
the mRNA expression of IL-6, 
EGFR and HB-EGF. Opposing 
to HL-7702 cell line, PLC/
PRF/5, with a moderate level 
of TLR4 expression, was not 
affected by inhibiting p38
Indicate that TLR4 signaling 
in cancer cells promotes cell 
survival and proliferation in 
HCC
Liu et al[50] 2015 March Experimental Two HCC cell lines and a 
splenic vein metastasis of the 
nude mouse model were used. 
A total of 88 clinical samples 
from HCC patients were used. 
A fluorescence activated cell 
sorting system and flow cytometry 
analysis were performed. Nude 
mouse splenic vein metastasis 
assay, immunohistochemistry 
analysis, real-time quantitative 
PCR, Western blot analysis, 
immunofluorescence and cell 
apoptosis assay were also done
More pathological specimens 
should be enrolled to verify 
the tendencies of association 
between TLR4 expression and 
malignant characteristics of 
HCC found in this study. A 
particular signaling pathway 
involved in the relationship 
between TLR4 expression and 
stem cell features remains 
elusive
There is a relationship 
between TLR4 expression 
and CSC's features, TLR4 
may act as a CSC marker, 
prompting tumor invasion 
and migration, which 
contributes to the poor 
prognosis of HCC
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Li et al[52] 2014 
October 
Experimental A HCC cell line was used where 
a Scratch assay was performed. 
Invasion assay, Western blot 
analysis, quantitative real-time 
reverse transcription PCR and 
siRNA knockdown of TLR4 gene 
expression were also done
It does not reveal the time 
needed for induction of 
epithelial-mesenchymal 
transition after LPS stimulus. 
Does not explore influence of 
LPS on TLR2
TLR4/JNK/MAPK signaling 
is required for LPS-induced 
EMT, tumor cell invasion 
and metastasis, which 
provide molecular insights 
for LPS-related pathogenesis 
and a basis for developing 
new strategies against 
metastasis in HCC
Jing et al[53] 2012 
August
Experimental Four HCC cell lines and a splenic 
vein metastasis of the nude mouse 
model were used and stable TLR4-
expressed and knocked-down cell 
lines were generated. 106 clinical 
samples from HCC patients were 
also used. Quantitative real-
time PCR, Western-blot analysis, 
Immunofluorescence, FACS 
Analysis and IHC analysis were 
performed
HCC development is a 
multifactorial and complicated 
process, which has a close 
association with various risk 
factors. Many gene alterations 
and cytokines also could 
induce EMT. HCC cells with 
low expression or even a lack 
of TLR4 are not susceptible 
to LPS, they might perform 
EMT induced by other TLR4-
independent mechanisms
TLR4 signaling is required 
for LPS-induced EMT, tumor 
cell invasion and metastasis, 
which provide molecular 
insights for LPS-related 
pathogenesis and a basis for 
developing new strategies 
against metastasis in HCC
Xu et al[54] 2014 
October
Experimental HCC and adjacent tissues were 
obtained from 84 patients. HCC 
cell lines were used and a PLV-
PTPRO-GFP plasmid was 
constructed. Real-time PCR, 
immunofluorescence, Western blot 
analysis and cell proliferation assay 
were performed
It does not specify the doses of 
NF-κB specific inhibitor needed 
to result in a decreasing of 
PTPRO's levels in HuH7 cells 
stimulated with LPS
The effect of PTPRO on 
TLR4 signaling is dependent 
on NF-κB pathway, 
suggesting an interesting 
PTPRO/TLR4/NF-κB 
signaling feedback loop in 
HCC carcinogenesis and 
progression
Wang et al[55] 2015 
January
Experimental It was used LPS-induced human 
hepatocellular carcinoma cell 
lines. Cell viability was assessed 
using the MTT assay. Double 
staining for annexin V-FITC and 
propidium iodide was performed. 
Inflammatory mediators were 
evaluated through a specific ELISA 
kit. Immunoprecipitation and 
Western blot analysis were also 
used
Only one type of cell line is 
used to observe the effect of 
CXC-195. It does not reveal 
the level (high or low) of TLR4 
expression. It does not explore 
the influence of LPS in TLR2
Treatment with CXC195 
could attenuate the TLR4-
mediated proliferation and 
inflammatory response in 
LPS-induced HepG2 cells
Yu et al[56] 2010 
October
Experimental Rats and mice were used, 
including TLR4-deficient mice. 
Immunohistochemical analysis and 
bone marrow transplantation were 
performed
It does not explore the effect 
of modulating gut flora. It 
does not evaluate the effect of 
different LPS' levels
Sustained LPS accumulation 
represents a pathological 
mediator of inflammation-
associated HCC and 
manipulation of the gut 
flora to prevent pathogenic 
bacterial translocation
Lin et al[58] 2012 
September
Experimental It was used wild-type and TLR4-
deficient mice. A flow cytometry 
analysis and Isolation and Culture 
of CD4+ cells were performed
TLR4 knockout showed 
decreased liver injury induced 
by Con A, contrarily to what 
was expected. It is needed to 
determine whether the regimen 
with antiendotoxin effects will 
prove beneficial in preventing 
or delaying T cell-mediated 
hepatitis and hepatitis-induced 
HCC
Gut-derived LPS and TLR4 
play important positive roles 
in Con A-induced hepatitis 
and modulation of the gut 
microbiota may represent a 
new avenue for therapeutic 
intervention
Chen et al[60] 2013 July Experimental It used HCV Tg mouse models 
and patients with HCC functional 
cDNA. Then, functional cDNA 
screening for oncogenes was 
performed. In vitro and in vivo 
oncogenic activities were evaluated. 
It was also done a liver TIC 
engraftment via splenic injection
The degree of attenuation of 
TLR4 expression in TICs by 
Nanog, implying a feedback 
loop is not shown. Besides this, 
the underlying mechanisms are 
not known
TLR4/NANOG oncogenic 
pathway is linked to 
suppression of cytostatic 
TGF-β signaling and could 
potentially serve as a 
therapeutic target for HCV-
related HCC
French et al[63] 2013 
August
Experimental Liver biopsies from patients 
diagnosed with alcoholic 
hepatitis, with or without 
cirrhosis were selected. Double 
Immunohistochemistry was 
performed
The antibody stain was only 
against TLR4
The Mallory-Denk-bodies 
forming cells expressed two 
additional progenitor cell 
markers. These markers 
were CD49f and TLR4
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Machida et al[64] 2014 
November
Experimental An immunostaining of liver tumor 
sections from alcohol-fed Ns5a 
mice was performed along with 
TLR4 silencing with lentiviral 
short-hairpin RNA
LPS-independent mechanisms 
of TLR4 activation in TICs 
remain to be elucidated. The 
oncogenic role of TLR4 is 
explored only around the 
synergism alcohol-HCV
TLR4-dependent 
mechanisms of TIC 
generation actually 
contribute to or at least 
promote the initiation of 
HCC
Yan et al[65] 2012 June Experimental Human HCC liver samples and 
mice were used. Stable HMGB1-
expressing cells and HMGB1 
knockdown cells were established. 
immunoblotting analysis, 
RNA Interference by short 
interfering RNA, enzyme-linked 
immunosorbent assay, confocal 
microscopy exam, caspase-1 
colorimetric assay, cell migration 
and invasion assays and metastatic 
potential exam were all performed
Mechanisms by which 
caspase-1 affects tumor 
cancer progression remain 
incompletely understood
In hypoxic HCC cells, 
HMGB1 activates TLR4- and 
RAGE-signalling pathways 
to induce caspase-1 
activation which, in turn, 
promote cancer invasion and 
metastasis
Xu et al[67] 2008 
February
Analytic - 
cross sectional
52 patients were studied. The 
protein and mRNA levels of 
TLR7 and TLR9 were evaluated 
using real-time PCR, Western 
blot analysis, and flow cytometry. 
We also detected the serum viral 
load of HBV in the patients and 
analyzed the correlation between 
HBV-DNA copies and the TLR 
expression
The statistical analysis indicated 
no difference in the TLR9 levels 
among the HCC and LC groups. 
If the sample size was enlarged, 
the results may be different. 
The expression of TLR7 was not 
different among the groups of 
patients, suggesting that TLR7 
has no correlation with HCC
There are downregulations 
of TLR7 expression and TLR9 
mRNA in PBMC of HBV-
infected patients, but an 
increased TLR9 expression at 
the protein level
Tanaka et al[68] 2010 
October
Experimental HCC cell lines and 42 HCC 
tissues were used. The type C 
CpG oligonucleotide was used 
as TLR9 ligand. Flow cytometric 
analysis, Immunohistochemical 
staining, Cell proliferation assay, 
Immunoblotting, NF-κB activity 
assays and expression analysis 
of IRF-7, RNA extraction and 
oligonucleotide microarray and 
Microarray data analysis were all 
performed
Despite being present both 
intracellular or extracellular 
TLR9's intracellular function is 
not observed with TLR9 ligands 
and its function is not known
Functional cell surface 
expression of TLR9 in human 
HCC may play an important 
role in tumorigenesis and 
cancer progression
Liu et al[69] 2015 
February
Experimental C57BL6 mice were injected with 
Hepa1-6 cancer cells. TLR9 and 
HMGB1 were inhibited using 
shRNA or direct antagonists. HuH7 
and Hepa1-6 cancer cells were 
investigated in vitro to determine 
how the interaction of HMGB1 and 
mtDNA activates TLR9 signaling 
pathways
The contribution of TLR9 
to cancer pathophysiology 
remains incompletely 
understood. The regulation 
of TLR9 signaling and the 
physiological ligands which 
may induce TLR9 mediated 
tumor growth remain poorly 
characterized
Reveals a novel mechanism 
by which the interactions 
of HMGB1 and mtDNA 
activate TLR9 signaling 
during hypoxia to induce 
tumor growth
Zhang et al[70] 2014 
December
Experimental It was used HCC cell lines to 
where was transfected CpG 
oligodeoxynucleotide and poly 
(I:C). Proliferation analyses, 
Detection of apoptosis with 
an Apoptosis Detection Kit, 
quantitative real-time PCR 
analysis, Western blot analysis and 
Fluorescence microscopy were also 
performed
The precise molecular 
interactions that likely occur 
between CpG ODNs and poly 
(I:C) to block poly (I:C) entry, 
remain to be established. 
Poly (I:C) may be influenced 
by many molecules in the 
microenvironment
When combining poly (I:C) 
and CpG ODN for cancer 
therapy, these agents should 
be used in an alternating 
rather than simultaneous 
manner to avoid the blocking 
effect of phosphorothioate-
modified TLR9 ligands
Zhang et al[71] 2014 April Experimental Human hepatoma cell lines were 
used. Cells were transfected with 
CpG ODNs or small interfering 
RNAs targeting TLR9. Reverse 
transcriptase polymerase chain 
reaction assay, Proliferation 
measurements, cell cycle analysis, 
detection of apoptosis, quantitative 
real-time PCR analysis, Western 
blot analysis were all performed. 
An in vivo study was also done
Apoptosis induced by ODN 
M362 Ctrl and ODN M362 
occurred independently of 
TLR9 stimulation. TLR9- 
and MyD88-independent 
mechanisms in ODN-stimulated 
immune cells, including B 
lymphocytes and neutrophils 
may exist
Phosphorothioate-modified 
TLR9 agonist ODN M362, 
and its control, elicit 
antitumor activity in HCC 
cells and may serve as a 
novel therapeutic target for 
HCC therapy
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Bubici et al[74] 2004 
December
Perspective Induction of FHC and 
Mn-SOD represents an 
additional, indirect means 
by which NF-κB controls 
proapoptotic JNK signaling
Liu et al[75] 2009 April Experimental Cell cultures were used. 
Immunocytochemistry stain for 
TLR9, a Cell proliferation assay, 
reverse transcriptase PCR for TLR9 
and real-time reverse transcriptase 
PCR for DNMT-1 and Bcl-2, NF-
κB activation measurement and 
Cellular apoptosis analysis were all 
performed
L-02 cells were used to allow 
in vitro studies but cells may 
behave differently in vivo. 
Future in vivo models are 
needed
Identified a possible novel 
mechanism that indicates 
how CpG DNA of HBV 
DNA may contribute to the 
malignant transformation of 
benign liver cells
Nischalke et al[76] 2012 March Analytic - 
cross sectional
A total of 197 patients with HCV-
associated HCC, 192 HCV-infected 
patients without HCC and 347 
healthy controls were included. 
HCV antibodies were detected 
for diagnosis. Determination 
of TLR2-196 to -174 del/ins 
polymorphism was performed by 
LightCycler real-time PCR. In vitro 
induction of TLR2 expression and 
IL-8 was performed
Analysis of the functional role 
of TLR2-196 to -174 del/ins 
alleles with respect to TLR2 
expression was based on in vitro 
stimulation studies but it is not 
known if an in vivo analysis 
would have the same results
TLR2-196 to -174 del allele to 
affect HCV viral loads and 
to increase the risk for HCC 
in HCV genotype 1-infected 
patients
Junjie et al[77] 2012 
February
Single center-
based case-
control
SNaPshot method was used to 
genotype sequence variants of 
TLR2 and TLR9 in 211 patients 
with HCC and 232 subjects as 
controls
Despite the SNP rs3804099 and 
rs3804100 were out of HWE (P 
= 0.01-0.02), they were retained 
in the analyses
TLR2 rs3804099 C/T 
and rs3804100 C/T 
polymorphisms were closely 
associated with HCC. In 
addition, the haplotypes 
composed of these two 
TLR2 synonymous SNPs 
have stronger effects on the 
susceptibility of HCC
Jiang et al[79] 2014 
December
Single center-
based case-
control study
426 HCC subjects and 438 cancer-
free control subjects were used. 
SNP genotyping was performed. 
A Vector was constructed and 
luciferase reporter assays were 
done. TLR4 mRNA levels were 
evaluated and Western blotting 
was done
The hypothesis that the 
overexpression of TLR4 induced 
by the rs1057317 polymorphism 
miRNA-disrupting function 
may influence the development 
of hepatocellular carcinoma is 
possible but still not proved. 
More studies in this area are 
needed
The risk of hepatocellular 
carcinoma was associated 
with a functional variant at 
miR-34a binding site in TLR4 
gene. miR-34a/TLR4 axis 
may play an important role 
in the development of HCC
Minmin et al[80] 2011 April Analytic-case-
control
A systematic genetic analysis of 
sequence variants of TLR4 by 
evaluating ten single-nucleotide 
polymorphisms was performed 
from 216 hepatocellular carcinoma 
cases and 228 controls
The contribution of the SNPs in 
TLR4 to HCC is modest. More 
studies are needed to validate 
this finding in independent 
populations and to understand 
the mechanism by which TLR4 
sequence variants affect the 
pathological role of TLR4 in the 
signaling pathways that control 
carcinogenesis
The risk of hepatocellular 
carcinoma was 
associated with TLR4 
sequence variation. 
TLR4 single nucleotide 
polymorphisms may play 
an important protective 
role in the development of 
hepatocellular carcinoma
Kawamoto et al[82] 2008 April Experimental Mouse cells were used together 
with plasmids containing TLRs. 
Cells were submitted to LPS and 
TAK-242. Nitrite and TNF-α were 
measured. Reporter gene assay 
for ligand-dependent signaling 
by TLRs, Reporter gene assay for 
ligand-independent signaling 
by TLR4, CD4-TLR or adaptors 
and Western blot analysis were 
performed
Human studies are needed 
as the interacting affinity of 
TAK-242 with TLR4 may be 
affected by a subtle difference 
in the amino acid sequences of 
TIR between humans and mice
TAK-242 selectively 
suppresses TLR4-signaling 
mediated by the intracellular 
domain
Matsunaga et al[83] 2011 
January
Experimental 293 cells of human embryonic 
kidney and murine resident 
peritoneal macrophages were used. 
They were subited to TAK-242 
and LPS. Vectors for FLAG-TLR4 
and FLAG-TLR2 were cloned. 
Measurement of nitrite and 
To fully understand the physical 
basis whereby TAK-242 
disturbs signaling complex 
formation and intracellular 
signal transduction, a crystal 
structure analysis of the TLR4-
TAK-242 complex is needed
TAK-242 binds selectively 
to TLR4 and subsequently 
disrupts the interaction 
of TLR4 with adaptor 
molecules, thereby inhibiting 
TLR4 signal transduction 
and its downstream 
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a “Myd88 independent manner/toll/interleukin-1 
receptor domain-containing adaptor protein inducing 
interferon beta (TRIF) dependent” with the extracellular 
signal-regulated kinase (ERK)/Junamino-terminal kinase 
(JNK) and PI3K/Akt pathways[24]. Besides this, TLR2 
signal is also involved in processes like autophagy and 
senescence in response to oxidative stress and DAMPS 
release[25].
Diethylnitrosamine (DEN) is a chemical carcinogen 
capable of inducing HCC through accumulation of 
reactive oxygen species (ROS) and endoplasmatic 
reticulum (ER) stress. It was found that when a TLR2-
deficient (TLR2-/-) mouse was submitted to DEN 
treatment the ROS and ER stress were abundantly accu-
mulated, even though less apoptosis was observed[25].
In fact, Lin et al[24] demonstrated, in two separated 
works, that both TLR2-/- and wild-type (WT) mice deve-
loped HCC after being submitted to a DEN-treatment. 
However, the TLR2-/- mice revealed earlier tumours 
(every TLR2-/- mouse developed HCC at 6 mo after DEN 
treatment vs only 68% WTs)[24] that were, not only 
significantly increased in number and in volume, but 
also less differentiated[24,25]. This increase reached the 3 
fold (20.1% ± 4.5% vs 6.4% ± 1.0%, P < 0.01) in the 
tumour area and 5 fold in visible tumour nodules (29.1% 
± 2.8% vs 5.5% ± 0.9%, P < 0.001)[24]. Meanwhile, in 
the WT mice, is possible to attenuate HCC development 
if a TLR2 agonist is used[26]. Ultimately, TLR2-/- mice 
had shorter mean survival times with HCC than WTs[24]. 
Moreover, similar scenery was observed when a WT was 
pre-treated with an anti-TLR2 antibody[25]. Indeed, when 
observing liver samples from patients in different stages 
of liver diseases it is notorious that, in patients with 
HCC, not only the mRNA levels of TLR2 are lower but 
also TLR2 immunohistochemical expression grade and 
intensity are reduced, when compared to patients with 
hepatitis or cirrhosis[27].
A ROS-generation reaction in cytochrome p450 
2E1 is responsible for DEN metabolism. In spite of not 
finding any significant difference in cytochrome activity, 
TLR2-/- mice still revealed enhanced accumulation of 
ROS in their liver tissue[24]. 
cytokine concentrations in culture 
supernatants, radiolabeling of 
the cells, immunoprecipitation, 
Western blot analysis and 
autoradiography, reporter gene 
assay and in vitro IL-1 receptor-
associated kinase-1 kinase assay 
were all performed
signaling events
Xu et al[84] 2013 
November
Experimental Four dsRNAs were designed 
and synthesized. The expression 
of proteins was compared. The 
migration, proliferation and 
apoptosis of HepG2.2.15 cells were 
evaluated in presence of BM-06, 
sorafenib alone or in combination 
of both. The similar treatments 
were also applied in an SD rat 
primary HCC model
Since synthetic siRNAs must 
be transfected into the target 
cells through a vector, such as 
Lipofectamine™ 2000 reagent, 
they always exhibit cytotoxicity, 
which may limit their use in 
clinic
dsRNA alone was capable of 
inhibiting the proliferation 
of HepG2.2.15 cells and 
tumor growth of orthotopic 
HCC SD rats, but the effect 
of combination of dsRNA 
with sorafenib was more 
prominent
Behm et al[85] 2014 
December
Experimental Rabbits were randomised to 
receive RFA, CpG B, their 
combination or no therapy, 
further tested by rechallenging a 
separate group with intravenously 
injected VX2 tumour cells after 
120 d. Animals were assessed for 
survival, tumour size and spread, 
and tumour and immune related 
histological markers after 120 d. 
Peripheral blood mononuclear cells 
were tested for tumour-specific 
T cell activation and cytotoxicity. 
Immune modulatory cytokines 
were measured in serum
Lack of antibody reagents 
for the VX2-tumour model 
in rabbits. It was not possible 
to elucidate in depth 
histopathological changes
The combination of TLR9 
stimulation with RFA 
resulted in a potentiated 
antitumour T cell response 
and cytotoxicity in the VX2 
tumour model. Only this 
combination prevented 
subsequent tumour spread 
and resulted in a significantly 
improved survival
TLR: Toll-like receptor; PCR: Polymerase chain reaction; HCC: Hepatocarcinoma; LPS: Lipopolysaccharides; TNF-α: Tumour necrosis factor α; DEN: 
Diethylnitrosamine; NAC: N-acetyl cysteine; MAPK: Mitogen-activated protein kinase; NF-κB: Nuclear transcription factor kappa B; ER: Endoplasmic 
reticulum; MDSC: Myeloid-derived suppressor cells; NAFLD: Non-alcoholic fatty liver disease; JNK: Junamino-terminal kinase; HMGB1: High mobility 
group box 1; INF-γ: Interferon gamma; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HSCs: Hepatic stellate cells; ODN: Oligodeoxynucleotides; 
NMOR: N-nitrosomorpholine; TNFR1: Tumor necrosis factor receptor 1; IL: Interleukine; DC: Dendritic cells; NK: Natural killer; HSCs: Hematopoietic 
stem cells; TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling; SA b-gal: Senescence-associated beta-galactosidase; ELISA: Enzyme-
linked Immunosorbent Assay; COX: Ciclo-oxigenase; IFC: Inflammation-fibrosis-carcinoma; ROS: Reactive oxigen species; HMGB1: High mobility group 
box 1; RAGE: Receptor for advanced glycation endproducts; HSP: Heat shock protein; HUVECs: Human umbilical vein endothelial cells; CSC: Colony 
stem cells; EMT: Epithelial-mesenchymal transition; TICs: Tumor-initiating cells; IRF: Interferon regulatory transcription factor; SNPs: Single nucleotide 
polymorphisms; HWE: Hardy-Weinberg equilibrium.
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Generation of ROS results in oxidative stress, which 
is often the source of DNA mutation or a direct link 
with chronic inflammation[28-30]. The ASK1/p38 MAPK/
NF-κB pathway is one of the major sensors for ROS 
accumulation contributing to induced senescence cell 
death when risk of mutation is present[31]. However, in 
TLR2-/- mice submitted to DEN treatment, it is possible 
to assist to an attenuation of this major pathway[25] 
together with a suppression of biomarkers of autophagy-
associated cell death and cellular senescence, like 
β-galactosidase[24]. Moreover, unlike the WT, TLR2-/- 
mice fail not only, to induce other important channels 
to premature cellular senescence like the p16-pRb/p21 
pathway[24], but also to activate DNA damage repair 
mechanisms[32]. 
Furthermore, ER-stress is augmented after DEN-
treatment in TLR2-/- mice as a result of ROS accumu-
lation[25]. This leads to an enhanced unfold protein 
response (UPR) and activation of UPR-JNK pathway[33], 
necessary for autophagy activation under ER-stress 
which, paradoxically, plays a dominant pro-survival 
role[34]. Lin et al[25] noticed that, in livers from TLR2-/- 
mice there was an increased JNK activity.
Overall this data indicates that in the absence of 
TLR2, a down-regulation of common ROS neutralizing 
mechanisms, due to supressed activation of ASK1/p38 
MAPK/NF-κB, results in HCC cells containing higher ROS 
and DNA damages that, because of an up-regulated 
UPR-JNK pathway, have more chances to survive. 
However, other pathways relating to TLR2 and 
hepatocarcinogenesis exist. Li et al[26] focus their 
work on IL-18, which was found to be fundamental 
to carcinogenesis in TLR2-/- mice. In these mice, HCC 
developing after DEN treatment was capable of inducing 
IL-18 up-regulation in a caspase-8-dependent manner, 
therefore contributing to promotion of angiogenesis 
and suppression of NK cell arm of tumour immunosur-
veillance[26]. 
Another perspective is related to the High mobility 
group box 1 (HMGB1), a nuclear protein released 
from dead/dying cells or even from cancer cells. It has 
the ability to bind to TLR2 and, with that, successfully 
activate NF-κB[35] which, in turn, can have an important 
role as a tumour promoter in inflammation-associated 
cancer[36]. Up-regulation of HMGB1 in an HCC cell line 
can result in increased matrix metalloprotease 9 and 
satellite tumour nodules in the liver, while blocking it 
supresses tumour growth[37]. A recombinant HMGB1 
(rHMGB1) was used by Shi et al[38] in order to simulate 
TLR2 activation in an HCC cell line. Interestingly, rHMGB1 
not only reduced cell apoptosis but also accelerated the 
tumour’s growth and enhanced the ability of migration 
and invasion. Additionally, rHMGB1 activity significantly 
declined when HCC cells were pre-treated with a TLR2 
inhibitor[38]. 
Similarly to HMGB1, HSPA1A - a member of the 
HSP70 family - is also a TLR2’s ligand released by the 
tumour’s necrotic cells. With a resembling pathway based 
on up-regulation of NF-κB, HSPA1A is capable of pro-
moting the proliferation and survival of tumour cells[39].
TLR2 clearly represents an important modulator of 
cells’ response to stress situations. It has influence in 
mechanisms like autophagy, apoptosis or even DNA 
damage repair, possibly contributing to a protective 
role against HCC. However, it is, also, important to 
notice that these pathways may not be, already, clearly 
understood as studies reveal that TLR2’s ligands like 
HMGB1 and HSPA1A, can result in tumour enhancement 
(Figure 2). 
Taken altogether this data suggests that TLR2 
activation may slow down initiation and development 
of HCC (anti-oncogenic potential) in the earlier phases 
of HCC carcinogenesis. However, at later stages its 
activation may influence the progression of inflammation 
and fibrosis (pro-oncogenic potential). Therefore, new 
studies are required in order to understand the exactly 
pathways through which this receptor is able to work 
and to conclude if its role in HCC carcinogenesis is 
different or not depending on the stage of the Inflam-
mation-fibrosis-carcinoma axis. 
TLR3
Several studies have already shown that TLR3 is 
expressed in many cancer cells such as colonic adeno-
carcinoma, lung cancer, breast cancer and melanoma. 
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Figure 2  Toll-like receptor 2’s signalling pathways contributing to 
hepatocarcinoma. In the absence of TLR2, cells are incapable of responding 
to an increasing ROS when submitted to DEN. This is the result of an absence 
of MAPK/NF-κB pathway and an up-regulation of the UPR-JNK pathway. 
Consequently, cells containing higher ROS and DNA damages have more 
chances to survive and, HCC develops. In a second stage, where HCC is 
already established, HMGB1 and HSPA1A released by tumour’s dying cells, 
through TLR2 stimulation, lead to an NF-κB up-regulation which, in this contest, 
seems to contribute to tumour’s growth. HCC: Hepatocarcinoma; TLR2: Toll-like 
receptor 2; ROS: Reactive oxigen species; DEN: Diethylnitrosamine; MAPK: 
Mitogen-activated protein kinase; NF-κB: Nuclear transcription factor kappa B; 
UPR: Unfold protein response; JNK: Junamino-terminal kinase; HMGB1: High 
mobility group box 1; HSPA1A: Heat shock protein A1A. 
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In HCC it was found that 17-fold longer median survival 
accompanied patients with higher intratumoral TLR3 
expression[40]. However, Yoneda et al[41] observed that 
52.7% of the HCC tissues and 34.8% of the HCC 
metastasis studied expressed TLR3. Furthermore, 
the receptor was not only present in the cytoplasm, 
but also in the membrane, particularly in the exterior, 
suggesting a cell surface recognition mechanism for 
TLR3 agonists[41]. 
Other works have already implied that the TRIF-
dependent pathway of TLR3 signalling could have a 
special contribution to a tumours response. In fact, this 
adaptor molecule can promote either an inflammatory or 
an apoptotic response. The first one pending on NF-κB, 
the second in caspase-8 activation and interferon-γ (INF-γ) 
release[42]. Experiments showed that using synthetic 
TLR3 agonists resulted in a rise in NF-κB. In fact, as 
it was seen with TLR2 signalling, NF-κB is normally 
associated with augmented tumour necrosis factor α 
(TNF-α) responsible for cells’ growth and proliferation[43]. 
However, here, an NF-κB rise is responsible for affecting 
the tumour microenvironment and driving HCC and 
endothelial cells to apoptosis[44], accompanied by a 
significantly decreased tumour invasiveness and angio-
genesis/vascular endothelial growth factor (VEGF) 
levels[45-47]. Thus, it seems that, whether NF-κB promotes
or inhibits hepatocarcinogenesis depends on the presence 
of inflammation and the degree of NF-κB inhibition/
promotion[3]. 
Moreover, INF-γ - a potent inhibitor of endothelial cell 
proliferation/angiogenesis - and caspase-8/caspase-3 - 
inhibitors of hepatocytes proliferation - were found to be 
significantly increased in HCC cell lines pre-treated with 
TLR3 agonists[48]. 
However, it is important to notice that, when 
stimulated through polyinosinicpolycytidylic acid, the 
surface TLR3 is only able to induce apoptosis if a protein 
synthesis inhibitor or a RNA synthesis inhibitor are 
present[41]. This might indicate that, in an HCC cell line, 
endogenous suppressors of TLR3-mediated apoptosis 
are present. Curiously, stimulation of intracellular TLR3, 
even without protein or RNA synthesis’ inhibitors, was 
able to elicit cell apoptosis in a tumour necrosis factor-
related apoptosis-inducing ligand-dependent manner 
that synergistically accompanies a down-regulation of 
anti-apoptotic proteins[41]. 
Notably, despite overall tumour growth could 
be reduced through TLR3 activation (from a 3-fold 
increase, when no TLR3’s stimulus is present, to an only 
1.9-fold increase after TLR3’s agonists being used), the 
number of tumour nodules increases even after eliciting 
TLR3 signalling, leading to the conclusion that it does 
not affects the incidence but limits their growth[47]. 
Interestingly, it appears that in HCC carcinogenesis 
TLR3 is a TLR that works as a protector against cancer. 
This is possible through molecules, downstream to TLR3, 
such as caspases, INF-γ or NF-κB, influencing crucial 
processes like angiogenesis, cell growth or proliferation 
(Figure 3).
TLR4
It is known that, despite being present in multiple liver 
cells, TLR4 expression is relatively low in this organ[49]. 
However, following liver damage and inflammation it is 
possible to assist to an up-regulation of this receptor[50]. 
Emerging evidence associates TLR4 to several types 
of tumours, enlightening its role in carcinogenesis, 
metastasis and cancer progression[51]. Observation of 
human’s livers detected a high expression of TLR4 in 
cancer cells of HCC patients[49].
Bacterial LPS is capable of initiating TLR4 signalling 
and subsequently activating NF-κB and MAPK signalling 
pathways - p38, ERK, JNK. In fact, in a HCC cell line 
incubated with bacterial LPS both TLR4 expression[52-54] 
and MAPK signalling pathways are significantly aug-
mented[52]. However, it was found that, in contrast with 
a normal hepatocytes cell line, in a HCC cell line, the 
cellular growth was augmented and the cytotoxicity 
induced by LPS was decreased and dependent on 
TLR4 expression (higher expression is equal to less 
cytotoxicity)[49]. Additionally, these effects are reduced 
after inhibiting TLR4 signalling[55].
The explanation of these results is based on two 
perspectives. One based on the fact that, in TLR4-
overexpressing cells, ERK and JNK’s activity is pro-
moted[49] contributing to cell survival and proliferation. 
Nonetheless, loss of TLR4 results in a substantial 
decrease in proliferating hepatocytes as well as in a 
reduced duration of JNK and ERK mitogenic signals[56]. 
This pro-survival effect, when facing LPS, can also be 
blocked by down-regulating this TLR4-downstream 
molecules - ERK and JNK[49]. 
 A second and slightly opposing situation relies on 
p38 - capable of inducing cell cycle arrest and apoptosis 
- and NF-κB - capable of stimulating pro-inflammatory 
cytokines (IL-1, -6, -10, TNF-α)[57] - that were inhibited 
by LPS, in a TLR4-overexpressing HCC cell line, allowing 
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agonist
TRAIL
Anti-apoptotic
proteins
Caspase-8 INF-γ
TLR3 agonist
TLR3
NF-κB
Augmented apoptosis and 
diminished angiogenesis
Less tumour growth
TL
R3
Figure 3  How toll-like receptor 3 stimulus works against hepatocarcinoma. 
Stimulation of intracellular TLR3 is able to elicit cell apoptosis in a TRAIL-
dependent manner that synergistically accompanies a down-regulation of 
anti-apoptotic proteins. Additionally, TLR3 stimulus can promote either an 
inflammatory or an apoptotic response. The first one pending on NF-κB, the 
second in caspase-8 activation and INF-γ release. As a result, TLR3 works as a 
protector against cancer which stimulation results in diminished tumour growth. 
TLR3: Toll-like receptor 3; TRAIL: Tumour necrosis factor-related apoptosis-
inducing ligand; INF-γ: Interferon gamma; NF-κB: Nuclear transcription factor 
kappa B.
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cell proliferation[49]. In fact, after stimulating TLR4, 
either blocking[49] or augmenting[39,55] NF-κB have been 
reported to promote tumour’s survival. Once more we 
face an ambiguity in interpreting NF-κB values. However, 
in this situation, the explanation can rely on the degree 
of the stimuli/block and the underlying inflammation[3]. 
Consequently, we are able to conclude that increased 
expression of TLR4 may protect HCC cells from LPS-
induced cytotoxicity and promote cell HCC survival and 
proliferation. 
This pro-tumorigenic effect of TLR4 is confirmed by 
the fact that, in TLR4-/- mice subjected to DEN, tumour 
incidence is 25% lower and diameters are smaller 
accompanied by less inflammation, proliferation as well 
as enhanced apoptosis[56]. Moreover, using antibiotics to 
reduce the LPS levels results in diminished activation of 
T helper 1 cells[58] and consequently less liver damage, 
and lower cell proliferation in tumour mass[56].
However, Xu et al[54] presented a different vision 
when reported increased expression of protein tyrosine 
phosphatase receptor type O (PTPRO) in TLR4-over-
expressing HCC cell lines after LPS treatment. Here, cell 
proliferation was inhibited and apoptosis was augmented 
as a result of the tumour suppressor capability of 
PTPRO[54]. To that end, it was found that, contrarily to the 
effects on LPS-induced cytotoxicity, TLR4-overexpression 
might also have a protective role through PTPRO and 
thus, worth being subjected to new studies. 
Li et al[52] also observed that, with TLR4 over-expre-
ssion, came a gradual disappearance of epithelial cell 
markers and increased mesenchymal ones, suggesting 
an epithelial-mesenchymal transition (EMT). This EMT 
is considered to be the molecular basis of tumour cell 
infiltration and metastasis[59] and can, actually, be 
induced by two possible pathways related to TLR4 and 
LPS stimulus. On one hand, the TLR4 - MAPK/JNK 
pathway, confirmed by the fact that, blocking directly 
MAPK/JNK or indirectly through TLR4, lead to inhibition 
of LPS-induced EMT[52]. On the other hand, Snail, a trans-
cription factor handled by NF-κB and a major inducer of 
EMT[53]. 
For this reason, LPS, via activation of TLR4 signalling 
pathway and consequently MAPK/JNK pathway activation 
or NF-κB up-regulation, can significantly induce EMT. 
This EMT phenotype is conveyed by cancer stem 
cells[60] which, in turn, are thought to be involved in 
processes like formation and progression of cancer, 
being, inclusively, responsible for chemotherapy resis-
tance, metastasis and postoperative recurrence[61,62]. 
Recent studies revealed that TLR4 positive cells exhibit 
a series of stem cells characteristics[50,60]. These cells not 
only display a higher invasive ability, when compared to
TLR4 negatives, but also express many stem cell markers 
(CD133 increase 85% when TLR4 is overexpressed[60]) 
as well as a stronger colony forming ability and increased 
chemotherapy/apoptosis resistance[50].
In agreement with these results, Chen et al[60] 
proposed that TLR4 could work as a proto-oncogene 
which aberrant expression/activation leads to induction 
of pluripotency genes and genesis of tumour-initiating 
stem-like cells (TICs). This process is possible through 
activation of a TLR4/NANOG pathway[60,62-64] and 
consequent inhibition of the transforming growth factor 
β (TGF-β)[60,62,64].
NANOG is per se a core transcription factor found 
in pluripotent stem cells[62]. TGF-β is an effective pro-
liferation inhibitor and an apoptosis promoter that, 
when down-regulated, is able to initiate tumorigenesis 
via stemness gene induction in an epithelial tissue such 
as liver[60]. In fact, knockdown of TLR4 attenuated the 
induction of stem cell genes as well as DNA synthesis of 
TICs in 50% to 80% and blocking NANOG, results in a 
tumour growth reduction of 60% to 75%[60].
However, some cancer cells grow efficiently in vitro 
without addition of LPS but this growth is still reduced by 
TLR4 knockdown, suggesting LPS-independent mecha-
nisms of TLR4 activation in these cells[64]. One possibility 
includes non-LPS ligands influencing tumorigenesis 
through TLR4 signalling. 
Yan et al[65] observed that hypoxia was also re-
sponsible for TLR4 up-regulation in an HCC cell line. 
Hypoxia is a hallmark of several solid tumours, including 
HCC, and an important factor in tumour progression[66]. 
A possible explanation of this relationship may involve 
hypoxia-induced HMGB1 release, capable of activating 
TLR4 signalling and consequently augment caspase-1. 
This one is, in turn, related with maturation of pro-
inflammatory cytokines and consequent tumorigenesis 
and tumour progression. After TLR4 blockage, caspase-1 
expression diminished significantly[65]. Additionally, 
caspase-1 blocking was capable of decreasing HCC cell 
invasiveness[65]. This suggests that hypoxia-induced 
caspase-1 activation, as well as caspase-1-mediated 
tumour progression, can depend on TLR4 signalling.
In spite of several evidences attributing a pro-
tumorigenic role to TLR4, the pathways to that end 
are many and still not fully understood. Diminished 
apoptotic-response to LPS, EMT-induction or caspase-1 
up-regulation through TLR4 were already proposed 
but, opposing effects mediated by tumour suppressors 
like PTPRO were also found (Figure 4). According to 
these results new studies are suggested to clarify not 
only how each work, but also how they are related. 
However, contrarily to TLR2 most data suggests that 
TLR4 activation not only has an important role in 
inflammation and fibrosis but also in HCC initiation and 
progression.
TLR9
A possible relationship between TLR9 and carcino-
genesis came to light when its high expression levels of 
TLR9 were found in samples of lung and breast cancer 
cell lines[67]. HCC cells exhibit a broad repertoire of 
TLRs, also including TLR9. This receptor plays a crucial 
role in cell survival as it recognises several bacterial and 
viral components, including unmethylated CpG-DNA. 
Different works revealed that there is an augmented 
TLR9 positivity in human HCC cells[8,68,69] with Eiró et al[8] 
Lopes JAG et al . Hepatocarcinoma and toll-like receptors
177 January 28, 2016|Volume 8|Issue 3|WJH|www.wjgnet.com
showing a TLR9’s prevalence of 60% (in a population 
of 30 cases) and Tanaka et al[68] reaching the 85.7% (in 
a population of 42 cases) in their works with human
samples of HCC. Moreover, in the later, 7 of 8 cases of 
HCC metastasis presented TLR9 positivity[68]. Additionally, 
it was found that, in both HCC cell line or HCC human 
samples, TLR9 was present not only in the cytoplasm 
but also on cells’ membrane[68]. However, is important to 
notice that, possibly, only the stimulation of membrane 
receptors could result in increased cell viability as 
transfecting a TLR9 agonist, CpG-oligodesoxynucleotide 
(CpG-ODN), which stimulates intracellular TLR9 re-
ceptors, may not affect proliferation and survival[68]. The 
explanation for this tumour-promoter role of TLR9 comes 
from the fact that, after TLR9 stimulation, a HCC cell line 
is able to, not only up-regulate apoptosis inhibitors such 
as survivin, Bcl-xL, XIAP and cFLIP, but also, to closely 
modulate oncogenic genes with a major contribution in 
tumorigenesis and cancer progression[68] (Figure 5). 
Although, this data is not that linear, and, somehow, 
different from what Zhang et al[70,71] stated in their 
studies. Here, transfecting a TLR9 agonist into a HCC 
cell line lead to a marked increase in IFN-α, IFN-β, 
TNF-α, IL-6 and IL-8 without activating NF-αB. As a 
result a cell-proliferation’s inhibition rate was increased 
approximately 50% and apoptosis was augmented[70,71]. 
The contradictory findings about the influence on 
tumour’s environment of intracellular TLR9 agonists 
could be explained by the fact that the phosphorothioate-
modified backbone of CpG-ODN are able to form a 
complex with or cause conformational changes in other 
compounds, like Poly (I:C) that, normally would result in 
enhanced apoptosis but, when together with CpG-ODN, 
are unable to act[70]. Moreover is important to look at the 
protocols used, as CpG-ODN induces HCC cell apoptosis 
in a dose-dependent manner, at concentrations below 0.5 
μg/mL. In contrast, high concentrations of this agonist 
(e.g., 5 μg/mL) had no effect on HCC cells[71]. 
Additionally, this pathway from TLR9 signalling 
to carcinogenesis is supported by HMGB1. We have 
already seen that HMGB1 and hypoxia could influence 
tumorigenesis through different TLRs. Interestingly, 
they are, also, both involved with TLR9. It was seen 
that along with TLR9 overexpression, hypoxic cancer 
cells accumulate structurally and functionally abnormal 
mitochondria, which release mitochondrial DNA (mt-
DNA) to the cytosol, and induce translocation of HMGB1 
from nucleus to cytoplasm[69]. The role of HMGB1 as a 
promoter of invasion, metastasis and angiogenesis when 
its location is extracellular is not new[72]. However, Liu 
et al[69] revealed that, on top of this, an cytoplasmatic
HMGB1-mtDNA interaction is required for complete 
activation of TLR9 signalling cascade and therefore 
essential for HCC cells to proliferate under hypoxic 
conditions. The underlying mechanism in this pro-tumo-
rigenic pathway lies in MAPKs activation - fundamental 
in growth, proliferation, differentiation and migration[73] 
- and also in NF-κB signalling - capable of suppressing 
apoptosis in response to stress[74] - after the interaction 
between HMGB1/mtDNA and TLR9[69,75] (Figure 5).
TLRS GENETIC POLYMORPHISMS AND 
VARIANTS AND HCC SUSCEPTIBILITY 
Several authors have already focused their studies on 
the relationship between TLRs’ genetics and carcino-
genesis, approaching different cancers such as non-
Hodgkin lymphoma, endometrial cancer, cervical cancer, 
non-cardiac gastric cancer, among others. 
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Figure 5  Toll-like receptor 9’s signalling pathways influencing hepatocar-
cinoma. TLR9 is present not only in the cytoplasm but also on cells’ membrane. 
However, it is still controversial whether cytoplasmatic stimulation results 
in increased cell viability. Independently, membrane receptors’ stimulation 
results, not only, in up-regulation of apoptosis inhibitors such as survivin, 
Bcl-xL, XIAP and c-FLIP, but also, in a modulation of oncogenic genes with 
a major contribution in tumorigenesis and cancer progression. Additionally, 
a cytoplasmatic HMGB1-mtDNA interaction was proved to be capable of 
activating TLR9 and MAPK pathway as well as NF-κB leading to augmented 
survival, growth, proliferation, differentiation and migration of cancer cells. 
TLR9: Toll-like receptor 9; XIAP: X-linked inhibitor of apoptosis protein; c-FLIP: 
Cellular FLICE-Like inhibitory protein; MAPK: Mitogen-activated protein kinase; 
NF-κB: Nuclear transcription factor kappa B; HMGB1: High mobility group box 1.
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Figure 4  Toll-like receptor 4’s signalling pathways influencing hepato-
carcinogenesis. Bacterial LPS is capable of initiate TLR4 signalling and 
subsequently activate NF-κB and MAPK signalling pathways. In one hand, in 
a HCC cell line incubated with bacterial LPS both TLR4 expression and MAPK 
signalling pathways are significantly augmented, contributing to cell survival 
and proliferation. On the other hand, TLR4 over-expression contributes to 
an EMT through MAPKs pathway and Snail. Additionally, NANOG induces 
TICs’ formation. Both are considered to be the molecular basis of tumour 
cell infiltration and metastasis. HMGB1’s stimulation of TLR4 with caspase-1 
activation is related with maturation of pro-inflammatory cytokines and 
consequent tumorigenesis and tumour progression. TLR4: Toll-like receptor 4; 
LPS: Lipopolysaccharides; HCC: Hepatocarcinoma; MAPK: Mitogen-activated 
protein kinase; EMT: Epithelial-mesenchymal transition; TICs: Tumour-initiating 
stem-like cells; NF-κB: Nuclear transcription factor kappa B; HMGB1: High 
mobility group box 1.
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Genetic studies on the TLR2 gene have shown a 
number of polymorphisms capable of interfering with 
host defenses and disease progression[76]. In fact, it was 
already seen that inherited variation in TLR2 influence 
the risk of HCC. Genetic TLR2 analysis revealed that 
two single nucleotide polymorphisms (SNP), rs3804099 
and rs3804100, had a significantly different distribution 
between HCC patients and the healthy controls[77]. 
Interestingly, in what is concerned to these SNPs, Junjie 
et al[77] suggested that, TLR2 gene variation could play 
an important protective role in HCC as the heterozygous 
genotype comprise lesser HCC risk (OR from 0.331 
to 0.759, P < 0.001) when compared to wild-type 
homozygous genotype. In fact, individuals carrying 
the TT haplotype had a significantly decreased risk of 
HCC [odds ratio (OR) = 0.524, 95%CI: 0.394-0.697, 
P < 0.001]. Contrarily, the CC haplotype had greater 
risk (OR = 2.743, 95%CI: 1.915-3.930, P < 0.001). 
Unfortunately, the authors do not reveal the real 
influence of the referred SNPs on the TLR2’s activity and 
more studies are suggested to clarify this information. 
Moreover, the frequency of a -196 to -174 deletion 
allele was, also, significantly higher in HCC patients 
than in healthy controls (22.5% vs 15.3%) and HCV-
infected patients without HCC (22.5% vs 15.6%)[76]. 
Nischalke et al[76] observations indicate that the -196 to 
-174 deletion allele possibly augment the risk of HCV-
induced HCC, probably as a result of diminished TLR2 
signalling and thus increased viral loads. This -196 
to -174 deletion not only had greater viral loads than 
-196 to -174 ins/ins but also, contribute to a 3-fold 
increase in HCC risk relatively to this -196 to -174 ins/
ins when both are compared to healthy controls or a 
1.5 fold increase when both are compared to hepatitis C 
patients without HCC[76].
Researchers have already studied the possible 
presence of polymorphisms in the area of TLR3. It was 
found that, at least in the chinese population, a +1234CT 
polymorphism is present which might contribute to 
increased susceptibility to HCC (specially 1234CT and TT 
genotypes)[78]. The presence of this SNP is responsible 
for a markedly diminished TLR3 function, which may 
result in up-regulated vasculature remodelling and 
tumour growth and, in that way, contributing to HCC[78]. 
The TLR4 is probably the more extensively studied 
TLR and therefore, not an exception when it comes to 
having polymorphisms or variants capable of influence 
carcinogenesis. Growing evidence has shown that TLR4 
polymorphisms are related to chronic inflammation 
and inflammatory-related cancer. As a matter of fact, 
a polymorphism in microRNA-34a binding site in TLR4 
(rs1057317) was significantly associated with higher 
HCC risk, especially in HBsAg (+) patients and in the AA 
homozygous genotypes[79]. MicroRNA-34a is capable of 
inducing apoptosis, G1 arrest and senescence explaining 
why its down-regulation may be associated with 
malignancy. However, there are not only polymorphisms 
related to augmented risk. Indeed, some mutations 
of TLR4 gene - four SNPs in 5’-UTR (rs10759930, 
rs2737190, rs10116253 and rs1927914) and one 
intron polymorphism (rs1927911) - may allow a two-
fold decrease in HCC risk, especially in heterozygous 
genotypes when compared to wild-type homozygous[80]. 
The justification can rely on the fact that 5’-UTR is 
involved in regulation of proteins concerned with growth 
and differentiation in normal tissues and these SNPs may, 
therefore, exert regulator effects in these proteins[80]. 
Therefore, according to the TLR4’s polymorphism 
observed, an augmented or diminished risk of HCC is 
possible, even though its magnitude is small. 
TLRS AS THERAPEUTIC TARGETS FOR 
HCC 
So far we have seen that different TLRs could work 
as specific modulators of HCC. Therefore it is logical 
to think that its use as therapeutic targets could open 
the door to new promising strategies in the fighting 
against HCC. In fact, the modulation of TLRs’ signalling, 
by targeting either the TLRs or their adaptors or 
downstream signalling molecules, is not new and they 
have already proved to be useful in ovarian, colorectal 
or head and neck cancer[81]. 
TLR4 modulators seem to be important chemo-
therapy adjuvants that enhance chemotherapy efficacy 
and prolong survival[81]. TAK-242 is a TLR4 ligand 
capable of selectively supress both ligand-dependent 
and independent signalling via the intracellular domain 
of TLR4, disrupting the TRAM and TIRAP interactions 
with TLR4[82]. This small molecule is, therefore, able 
to down-regulate NF-κB and consequently diminish 
inflammatory mediators such as nitric oxide, TNF-α, 
IL-1, -6 and with that, reduce the proliferation/invasion 
activity induced by LPS in the liver cancer cell lines[57,82,83]. 
Furthermore, TAK-242 might also show an efficacy 
against inflammation mediated by excessive expression 
of TLR4, what, in fact, has been shown to happen in 
HCC[82]. Independently, new studies are still required for 
better evaluating effects, doses and other characteristics 
of TAK-242. 
To date, we still lack an effective systemic curative 
therapy for advanced cases of HCC and, in most cases 
the only alternative is palliative treatment. 
Even though, sorafenib, a multi-kinase inhibitor, 
represents an important chemotherapeutic drug in 
the treatment of this type of cancer. Xu et al[84] found 
that a combination of sorafenib with a TLR3-synergist 
(BM-06) results in a superior inhibition of tumour growth 
in HCC cell lines or rat models when compared to the 
two different agents alone. Their results were based on 
a significantly reduced proliferative capacity, invasion 
ability, tumour volume and an increased apoptotic 
rate[84]. Therefore, BM-06 emerges as a possible 
adjuvant agent in the therapeutic against HCC.
In the TLR9 domain several studies were already 
conducted. It was reported that using TLR9 antagonists 
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like chloroquine could be useful in several autoimmune 
diseases[2]. In fact, a markedly reduced proliferation 
is seen in a HCC cell line when TLR9 is inhibited by 
chloroquine[2]. This antimalaric agent works as a direct 
TLR9 antagonist, being proposed that its activity on 
HCC cells may be brought about via its effects on the 
protein kinase AKT, tumour-associated angiogenesis 
factor VEGF as well as NF-κB. Moreover, the same 
tumour growth restriction, followed by smaller volume 
and reduction in tumour’s markers of aggressiveness 
was seen when this treatment was used in HCC cell 
lines intrahepatic implanted in mice[2]. 
However, as it was said, sometimes, the only option 
is the palliation and radiofrequency ablation (RFA) 
which has already established an important role in this 
setting. Behm et al[85] successfully demonstrated that, 
in a rabbit model, TLR9 agonists could work together 
with RFA in an anti-tumour response through a strong 
cytotoxic immune response mediated by increased 
tumour-specific lymphocytes. In fact, it was not only a 
good predictor of containment of tumour growth and 
spread but also of prolonged survival[85].
Moreover, some studies focus on the use of TLRs 
as vaccine’s adjuvants against HCV or HBV mediated 
hepatocarcinogenesis. There are also some proposals 
for using TLR4’s antagonists in patients with septic 
shock[86]. Besides this, the use of TLR4’s antagonists is 
being investigated in the prevention of alcoholic liver 
injury and Non Alcoholic Steato-Hepatitis[9]. 
Despite the good results, when it comes to using 
TLRs as a novel HCC therapeutic it still has a long run 
before every mechanism is understood. TLRs’ signalling 
pathways are too many and effects remain controversial 
but a lot is to be expected from these innate immunity 
receptors.
CONCLUSION
HCC occupies the third place when it comes to mortality 
in cancer[1]. Several factors are known to contribute to 
the carcinogenic process including viral hepatitis, alcohol, 
auto-immune or metabolic diseases, among others. The 
link between all these factors is inflammation or, more 
precisely, chronic inflammation.
However, despite all this malignant potential or this 
knowledge around the inflammatory causality, most of 
the pathways of carcinogenesis are still unknown or, at 
least, not entirely known. 
TLRs’ role in the tumour formation is part of a more
recent concept that involves innate immunity but, 
despite all the advances, a lot is still waiting to be 
studied. The reasons for this lack of information include 
the range of responses that can be obtained from 
a single TLR signalling. Humans dispose of 11 TLRs 
capable of initiating a signal cascade from only five 
molecular adaptors. Consequently, some can be used by 
more than one receptor. Moreover, each of this activated 
adaptor molecules, depending on the initial TLR, elicit a 
response based on the production of several effectors, 
pro-inflammatory or anti-inflammatory cytokines, 
interferons and many others with countless results.
To understand the role of TLRs we must remember 
that HCC comes from an inflammatory background 
where a complex and progressive process appears 
with fibrosis and cirrhosis until the last stage, HCC, 
is reached. This review tried to show that, the path 
taken can be closely influenced by innate immunity/
TLRs (Figure 6). TLR2 was shown to be an important 
stress manager so that, in its absence, an attenuated 
ASK1/p38 MAPK/NF-κB pathway and an increased JNK 
activity result in a larger and less differentiated HCC. 
Contrarily, TLR2’s stimulation through HMGB1 and 
HSPA1A also indicates a tumour-promoter role. TLR3 
may be responsible for driving HCC and endothelial 
cells to apoptosis and decreasing invasiveness and 
angiogenesis by mediating NF-κB, caspase-8 and INF-γ 
up-regulation. TLR4 is closely related to LPS cytotoxic, 
which is diminished in TLR4-overexpressing HCC due 
to promoted ERK’s and JNK’s activity and limited NF-
κB and p38 activation. Moreover, this receptor is tightly 
involved in EMT and progression of cancer based on 
non-LPS ligands like NANOG and HMGB1. TLR9 activity 
is different whether the membrane or the intracellular 
receptor is activated. The first promotes HCC through 
apoptosis inhibitors and oncogenic genes. The second 
augments apoptosis by increasing Interferons and 
interleukines. Consequently, initial findings attribute a 
pro-tumorigenic role to TLR4 and TLR9 and a protective 
capacity to TLR3. When it comes to TLR2, the available 
data suggests that its influence may go both ways (pro-
tumorigenic and protective) depending on the liver’s
stage in the inflammation-cirhosis-carcinoma axis. 
However this is not that simple or linear as a closer 
look easily reveals studies with interesting but opposing 
conclusions from the ones before. 
Independently of this lack of knowledge, one thing 
is certain; TLRs can have a determining influence on 
the cancer’s progression. Therefore, the usage of TLRs 
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Figure 6  Toll-like receptors influence on the pathway to hepatocarcinoma. 
Several factors are known to contribute to the carcinogenic process including 
viral hepatitis, alcohol, auto-immune or metabolic diseases, among others and 
the link between all this factors is chronic inflammation which, in turn, is an 
important hepatocarcinoma’s percursor. Moreover, innate immunity represents 
an important player in this equation with TLRs such as 4 and 9 having, mainly, a 
positive contribution to hepatocarcinogenesis and TLR3, essentially, a negative/
protective one. TLR2 still presents an ambiguous role, possibly depending 
on liver’s stage in the inflammation-cirrhosis-carcinoma axis to exert its pro-
tumorigenic or anti-tumorigenic capacity. TLR: Toll-like receptor.
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as therapeutic targets has already been established, 
especially as adjuvants to other agents currently in use. 
However, the possibilities are many and with a deeper 
insight over the mechanisms involved new ways of 
dealing with HCC are expected to emerge. 
In conclusion, we cannot say that TLRs came to 
facilitate our understanding of HCC mechanisms. Instead 
they came to open the door to a new reality and, with 
that, to possible new approaches, perhaps in a closer 
future than we might know. 
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Guidelines for Manuscript Preparation and Submission: Review 
 
You can use the following checklist to help you fulfill manuscript submission 
requirements. 
 
1 WRITING REQUIREMENTS [     ] YES or NO 
1.1 Title.  [     ]   
1.2 Running title.  [     ]   
1.3 Authorship.  [     ]  
1.4 Institution.  [     ]   
1.5 Author contributions.  [     ]   
1.6 Supportive foundations.  [     ]   
1.7 Conflict-of-interest statement. [     ]   
1.8 Correspondence to. [     ]   
1.9 Telephone and fax. [     ]   
1.10 Abstract. [     ]   
1.11 Keyword. [     ]   
1.12 Core tip. [     ]   
1.13 Citation. [     ]   
1.14 Main text. [     ]   
1.15 Units. [     ]   
1.16 Illustrations. [     ]   
1.17 Tables. [     ]   
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1.18 Notes in illustrations and tables. [     ]   
1.19 Abbreviations. [     ]   
1.20 Italics. [     ]   
1.21 Acknowledgments. [     ]   
1.22 References. [     ]   
 
2 LANGUAGE EDITING PROCESS FOR MANUSCRIPTS SUBMITTED BY NON-   
NATIVE SPEAKERS OF ENGLISH [     ] YES or NO 
 
3 STEPS TO SUBMIT MANUSCRIPTS [     ] YES or NO 
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1 WRITING REQUIREMENTS 
All contributions should be written in English. All articles must be prepared by Word-
processing Software, using 12 pt Book Antiqua font and 1.5 line spacing with ample 
margins. Required information for each of the manuscript sections is as follows: 
 
1.1 Title. The title should be no more than 12 words. The title should summarize the core 
content of the manuscript, so that the reader may readily understand the key concepts 
and important findings presented within. This type of succinct and impactful statement 
will serve to catch readers' attention and stimulate their interest in reading the abstract 
and/or downloading the full paper. It is also strongly recommended that the title 
include one or two of the key words associated with the manuscript’s topical content, to 
facilitate the paper being readily found by electronic searches of public databases, such 
as Google or PubMed. Finally, a succinct and impactful title will include minimal 
nonfunctional words, such as “a,” “an,” “the,” “roles of,” etc. and will avoid non-
standard abbreviations. 
 
1.2 Running title. A short running title of no more than 6 words should be provided. It 
should state the topic of the paper. 
 
1.3 Authorship. Authorship credit should be given in accordance with the standard 
proposed by the ICMJE (http://www.icmje.org/), specifically, authorship is merited by 
(1) substantial contributions to conception and design of the study, acquisition of data, 
or analysis and interpretation of data; (2) drafting the article or making critical revisions 
related to important intellectual content of the manuscript; and (3) final approval of the 
version of the article to be published. Authors should meet conditions 1, 2 and 3. Please 
note that the co-first author designation is not allowed for any Baishideng Publishing 
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Group (BPG) published article. 
 
1.4 Institution. Author names (unabbreviated) should be given first (first name and 
family (sur)name), followed by the complete name of the affiliated institution, city, 
province/state, postcode and country. For example, Xu-Chen Zhang, Li-Xin Mei, 
Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, 
China. In the case that one author represents two institutions, the institutions will be 
listed separately; for example, George Sgourakis, Department of General, Visceral, and 
Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical 
Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece. 
 
1.5 Author contributions. The format of this section will be as follows: Author 
contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, 
Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F 
and Wu XM performed the research; Xue JZ and Lu JR contributed new 
reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; Wang CL, Liang 
L and Fu JF wrote the paper. 
 
1.6 Supportive foundations. The complete name(s) of supportive foundations and 
identification number(s) of grants or financial support will be provided in the following 
format: Supported by the National Natural Science Foundation of China, No. 30224801. 
 
1.7 Conflict-of-interest statement. A conflict-of-interest statement is required for all 
article and study types. In the interests of transparency and helping reviewers to assess 
any potential bias in a study’s design, interpretation of its results or presentation of its 
scientific/medical content, the BPG requires all authors of each paper to declare any 
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conflicting interests (including but not limited to commercial, personal, political, 
intellectual or religious interests) in the title page that are related to the work submitted 
for consideration of publication. In addition, reviewers are required to indicate any 
potential conflicting interests they might have related to any particular paper they are 
asked to review, and a copy of signed statement should be provided to the BPG in PDF 
format. 
  
Sample wording: [Name of individual] has received fees for serving as a speaker, a 
[position; such as consultant and/or an advisory board member] for [name(s) of 
organization(s)]. [Name of individual] has received research funding from [name(s) of 
organization(s)]. [Name of individual] is an employee of [name(s) of organization(s)]. 
[Name of individual] owns stocks and/or shares in [name(s) of organization(s)]. [Name 
of individual] owns patent [patent identifier information (including patent number, two-
letter country code, and kind code) and a brief description]. 
  
1.8 Correspondence to. Only one corresponding author is allowed. The corresponding 
author’s contact information will be provided in the following format: Author names 
(unabbreviated) should be given first (first name and family (sur)name), followed by the 
author’s title, affiliation, the complete name of institution, city, province/state, postcode, 
country and email. All the letters in the email address should be typed in lowercase, and 
separated from the country by a period and a space. For example, Andrzej S Tarnawski, 
MD, PhD, DSc (Med), Professor of Medicine, Chief, Gastroenterology, VA Long Beach 
Health Care System, University of California, Irvine, 5901 E Seventh St, Long Beach, CA 
90822, United States. astarnaw@uci.edu 
 
1.9 Telephone and fax. Telephone and fax numbers should consist of +, country number, 
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district number and telephone or fax number; for example, Telephone: +86-10-85381892 
Fax: +86-10-85381893 
 
1.10 Abstract. An informative, unstructured abstract of no less than 200 words should 
accompany each manuscript.  
 
1.11 Keyword. Please list 5-10 keywords for each paper, which reflect the content of the 
study and are selected mainly from the Index Medicus. Each keyword is to be separated 
by a semicolon. 
 
1.12 Core tip. Please write a summary of no more than 100 words to present the core 
content of your manuscript, highlighting the most innovative and important findings 
and/or arguments. The purpose of the Core Tip is to attract readers’ interest for reading 
the full version of your article and increasing the impact of your article in your field of 
study. 
 
1.13 Citation. The citation contains, authors’ names and title. The name of the first 
author should be typed in bold-faced letters; the family (sur)name of all authors should 
be typed with the first letter capitalized, followed by their abbreviated first and middle 
initials. For example, an article by Jae Moon Yoon, Ki Young Son, Chun Sick Eom, Daniel 
Durrance, Sang Min Park will be written as Yoon JM, Son KY, Eom CS, Durrance D, Park 
SM. Pre-existing diabetes mellitus increases the risk of gastric cancer: A meta-analysis.  
 
1.14 Main text. The main text contains introduction, discussion, conclusion, and 
references. 
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1.15 Units. Use SI units. For example: body mass, m (B) = 78 kg; blood pressure, p (B) = 
16.2/12.3 kPa; incubation time, t (incubation) = 96 h, blood glucose concentration, c 
(glucose) 6.4 ± 2.1 mmol/L; blood CEA mass concentration, p (CEA) = 8.6 24.5 g/L; CO2 
volume fraction, 50 mL/L CO2, not 5% CO2; likewise for 40 g/L formaldehyde, not 10% 
formalin; and mass fraction, 8 ng/g, etc. Arabic numerals such as 23,243,641 (i.e. 23 
million, 243 thousand, and 641) should be written as 23243641, with no commas and no 
spaces. The format for how to accurately write common units and quantums can be 
found at: http://www.wjgnet.com/bpg/g_info_20100725073806.htm. 
 
1.16 Illustrations. Figures must be presented in the order that they appear in the main 
text of the manuscript (numbered as 1, 2, 3, etc.). All figures must have a detailed figure 
legend that provides a clear and comprehensive description of the information presented 
in the figure, so that the reader can understand without having to refer back to any other 
portion of the manuscript. The figure’s title and legend must be presented on a separate 
page from the figure itself.  
It is necessary to keep all elements compiled in a line-art image. Scale bars should be 
used rather than magnification factors, with the length of the bar defined in the legend 
rather than on the bar itself. Figure file names should identify the figure and panel. 
Avoid layering type directly over shaded or textured areas. Uniform presentation should 
be used for figures showing the same or similar contents; for example, “Figure 1 
Pathological changes of atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; 
F: ...; G: ...” 
Figures with labels, arrows or other markers, photographs, clinical images, 
photomicrographs, gel electrophoresis, and the like that include labels, arrows or other 
markers must be submitted in 2 versions: one version with the markers; and the other 
without. Provide an explanation for all labels, arrows, or other markers in the figure 
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legend. The figure field in the File Description tab of the manuscript submission form 
allows for uploading of 2 versions of the same figure. 
 
1.17 Tables. Tables must be presented in the order that they appear in the main text of 
the manuscript (numbered as 1, 2, 3, etc.). A brief, one-line title must be provided for 
each table. Detailed legends should not be included under tables, instead having the 
information presented in the main text where applicable; the information should 
complement, but not duplicate the text. Use one horizontal line under the title, a second 
under the column headings, and a third below the Table to be above any footnotes. 
Vertical line and italics should be omitted.  
Please note that tables embedded as Excel files within the manuscript are NOT 
accepted. Tables in Excel should be copied and pasted into the manuscript Word file. All 
tables will be located at the very end of your article document. Any tables submitted that 
are longer/larger than 2 pages will be published as online-only supplementary material. 
Tables must be primarily cell-based and fully editable. Do not use the following to 
organize data or structure the table: (1) Returns (“Enter” key); (2) Tabs; (3) Spaces; (4) 
Colored text; (5) Cell shading; and (6) Cells within cells. The Software should be Word 
(preferred), Excel. Don’t allow the graphics, boxes, or embedded tables appear in the 
manuscript. Don’t allow the parts to appear in the manuscript, if there are some parts, 
please make Table 1A and Table 1B into Tables 1 and 2, or combine into one table.  
 
1.18 Notes in illustrations and tables. Data that are not statistically significant should 
not be noted.  
Statistical significance in a figure or table should be denoted using superscripted 
alphabetical lettering, such that aP < 0.05 and bP < 0.01; non-significant values, i.e., P > 
0.05, usually do not need to be indicated. If there are other series of P values, the 
alphabetical subscripted denotation format is continued, such that cP < 0.05 vs control, dP 
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< 0.01 vs control, eP < 0.05 vs group A, and fP < 0.01 vs group B. 
Other notes in tables or under illustrations should be expressed as F1, F2, F3 or 
sometimes as other superscripted symbols (Arabic numerals). In a multi-curve 
illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, etc., in a specified 
sequence.  
 
1.19 Abbreviations. Standard abbreviations should be defined in the abstract and in the 
main body of the manuscript upon first mention in the text. In general, terms should not 
be abbreviated unless they are used three times or more and the abbreviation is helpful 
to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: 
A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published 
by The Royal Society of Medicine, London. Certain commonly used abbreviations, such 
as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, 
ATP, EDTA and mAb, do not need to be defined and can be used directly. 
 
1.20 Italics. Quantities: t time or temperature, c concentration, A area, l length, m mass, V 
volume.  Genotypes: gyrA, arg 1, c myc, c fos, etc.  Restriction enzymes: EcoRI, HindI, 
BamHI, Kbo I, Kpn I, etc.  Biological nomenclature: H. pylori, E. coli, etc. 
 
1.21 Acknowledgments. Brief acknowledgments of persons who have made genuine 
contributions to the manuscript and who endorse the data and conclusions should be 
included. Authors are responsible for obtaining written permission to use any 
copyrighted text and/or illustrations. 
 
1.22 References. This section includes Coding system, PMID and DOI, Style for journal 
references, Style for book references, and Format for references (Examples). Specific 
requirements are as follows:  
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(1) Coding system 
The author should number the references in Arabic numerals according to the citation 
order in the text. The reference numbers will be superscripted in square brackets at the 
end of the sentence with the citation content or after the cited author’s name. For citation 
content that is part of the narration, the coding number and square brackets should be 
typeset normally. For example, “Crohn’s disease (CD) is associated with increased 
intestinal permeability[1,2].” If references are cited directly in the text, they should be 
included with the direct citation content within the text; for example, “From 
references[19,22-24], we know that...”. Before submitting your manuscript, please ensure 
that the order of citations in text is the same as in the references section, and also ensure 
the spelling accuracy of the authors’ names. Do not list the same citation twice. 
 
(2) PMID and DOI 
Please provide the PMID number, which is the serial number that roots the abstract for 
that publication into the PubMed index, and the CrossRef DOI® (Digital Object Identifier) 
name, which is a unique string created to identify a piece of scholarly content in the 
online environment for each reference in the References section. The PMID number can 
be found at http://www.ncbi.nlm.nih.gov/pubmed and the DOI name can be found at 
http://www.crossref.org/SimpleTextQuery/.  The numbers will be used in the 
electronic (E)-version of the manuscript published by the WJG. 
 
(3) Style for journal references 
For authors’ names, the name of the first author should be typed in bold-faced letters; 
the family (sur)name of all authors should be typed with the first letter capitalized, 
followed by their abbreviated first and middle initials. For example, an article by Lian-
Sheng Ma and Bo-Rong Pan will be written as Ma LS and Pan BR. The title of the cited 
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article will be written in sentence case. The journal title will be written in its abbreviated 
form (as shown in PubMed) in italics and followed by the article publication information 
(not italicized), including the publication date, volume number (in bold-face numbers), 
and start page through end page (separated by a hyphen). The PMID and DOI will 
follow this information and be written as [PMID: 11819634 DOI: 10.3748/wjg.13.5396]. 
 
(4) Style for book references 
For the authors’ names, the name of the first author should be typed in bold-faced letters. 
The family (sur)name of all authors should be typed with the initial letter capitalized, 
followed by their abbreviated middle and first initials.. The book title will follow the 
authors’ names and not be italicized. The publication information will follow, written as 
punctuated here: publication number, publication place: publication press, year: start 
page - end page. 
 
(5) Format for references: Examples 
Print journals 
English language journal article (list all authors and include the PMID and DOI, 
where applicable): 
 
1 Jung EM, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung 
F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver 
tumors: A prospective controlled two-center study. World J Gastroenterol 2007; 13: 6356-
6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356] 
 
Chinese language journal article (list all authors and include the PMID and DOI, 
where applicable): 
2 Lin GZ, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen 
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decoction in treatment of Pixu-diarrhoea. Shijie Huaren Xiaohua Zazhi 1999; 7: 285-287 
 
In press article: 
3 Tian D, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in 
Arabidopsis. Proc Natl Acad Sci USA 2006; In press 
 
Organization as author: 
4 Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin 
in participants with impaired glucose tolerance. Hypertension 2002; 40: 679-686 [PMID: 
12411462] 
 
Both individual authors and an organization as author: 
5 Vallancien G, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. 
Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. 
J Urol 2003; 169: 2257-2261 [PMID: 12771764] 
 
No author given: 
6 21st century heart solution may have a sting in the tail. BMJ 2002; 325: 184 [PMID: 
12142303] 
 
Volume with supplement: 
7 Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with 
short- and long-term use for treatment of migraine and in comparison with sumatriptan. 
Headache 2002; 42 Suppl 2: S93-99 [PMID: 12028325] 
 
Issue with no volume: 
8 Banit DM, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision 
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total joint arthroplasty. Clin Orthop Relat Res 2002; (401): 230-238 [PMID: 12151900] 
 
No volume or issue: 
9 Outreach: Bringing HIV-positive individuals into care. HRSA Careaction 2002; 1-6 
[PMID: 12154804] 
 
Books 
Individual author(s): 
10 Sherlock S, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: 
Blackwell Sci Pub, 1993: 258-296 
 
Chapter in a book (list all authors): 
11 Lam SK. Academic investigator’s perspectives of medical treatment for peptic ulcer. 
In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: 
Marcel Dekker, 1991: 431-450 
 
Author(s) and editor(s): 
12 Breedlove GK, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wieczorek RR, editor. 
White Plains (NY): March of Dimes Education Services, 2001: 20-34 
 
Conference-related articles 
Conference proceedings: 
13 Harnden P, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th 
Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-
56 
 
Conference paper: 
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14 Christensen S, Oppacher F. An analysis of Koza's computational effort statistic for 
genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. 
Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on 
Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191 
 
Electronic journals 
Electronic journal (list all authors): 
15 Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis serial 
online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: 
http//www.cdc.gov/ncidod/EID/eid.htm 
 
Patents 
Patent (list all authors) 
16 Pagedas AC, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic 
grasping and cutting device and positioning tool assembly. United States patent US 
20020103498. 2002 Aug 1 
 
2 LANGUAGE EDITING PROCESS FOR MANUSCRIPTS SUBMITTED BY NON-
NATIVE SPEAKERS OF ENGLISH 
We will, with the right attitude and approach, cooperate with authors who are not native 
speakers of English so that they may successfully complete the final publication of their 
manuscripts. Quality control of a manuscript’s language is not negotiable with the BPG 
or any of its journals. The language of the manuscript must meet the requirements of 
academic publishing. 
    For manuscripts submitted by non-native speakers of English, the authors are 
required to provide a language editing certificate which will serve to verify that the 
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language of the manuscript has reached grade A. Before the manuscript is finally 
published, the language of the manuscript must also pass the proofreading test by an 
English language editor (native or non-native) who will be designated at the discretion 
of the journal’s editorial office. 
The language editing process for manuscripts submitted by non-native speakers of 
English is as follows: 
 
2.1 Language evaluation. Grade A: priority publishing; Grade B: minor language 
polishing; Grade C: intensive language polishing; Grade D: rejected. The language of 
revised articles should reach grade A.  
    Please pay careful attention to the details of the English language presentation of the 
paper prior to resubmission since author(s) are allotted only one opportunity for 
revision. 
    If you believe that the language of your manuscript has reached or exceeded Grade A 
without the need for employing a professional editing service, you may choose to sign a 
personal guarantee for the language presentation of your manuscript. However, if we 
find that the language of your manuscript has not reached Grade A, your paper will be 
rejected. 
 
2.2 Manuscript submission by authors. After the manuscript passes the preliminary 
review conducted by a science editor, it will be sent to peer reviewers for evaluation of 
its academic and language qualities. The language of manuscripts will be classified 
according to the following four grades: A (priority publishing), B (minor language 
polishing), C (a great deal of language polishing), and D (rejected). 
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2.3 Pending acceptance. The science editor will send the revised manuscript, along with 
the peer reviewers’ comments (including language quality evaluation), the CrossCheck 
reports and the documents regarding Academic Rules and Norms, to the authors. The 
documents regarding Academic Rules and Norms will include the Human and Animal 
Rights statement, the Institutional Review Board statement, the Informed Consent 
statement, the Clinical Trial Registration statement, the Institutional Animal Care and 
Use Committee statement, the Animal Care and Use statement, the Biostatistics 
statement, the Conflict-of-interest statement, and the Data sharing statement. 
 
2.4 Manuscript revision by authors. The authors’ attitudes towards the peer review 
process and the quality control process will also play a significant role in whether the 
manuscript garners final acceptance for publication. We require that authors carefully 
address each problem raised by the peer reviewers and the science editor, and revise 
their manuscript accordingly. 
 
2.5 Manuscript finalization by authors. Authors must complete the manuscript revision 
based on the peer reviewers’ comments and advice, and to ensure that their contents 
correspond to the academic rules and norms. In addition, authors must also format all 
charts and images, tables, and references according to the journal-specific requirements 
as well as those specified by the science editor. 
 
2.6 Manuscript language editing by authors. We strongly recommend that authors use 
language editing services provided by the following biomedical editing companies, 
based on their good reputation and reliable quality: 
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Jing-Yun Ma Editorial Office: http://majingyun.baikemy.com 
American Journal Experts: http://www.aje.com 
Nature Publishing Group Language Editing: http://languageediting.nature.com 
   These companies often provide several different types of language editing services, 
typically including proofreading, standard editing, extensive editing and rewriting. We 
strongly recommend that authors use the extensive editing service so as to completely 
address the language problems of the manuscript. For example, extensive editing will 
involve editing the manuscript for proper grammar and spelling and the correct usage of 
articles, prepositions, conjunctions, abbreviations, punctuation, italic font of Latin words, 
biomedical terms, tenses, active voice and passive voice, and sentence structure, as well 
as checking of the academic rules and norms, and for scientific misconduct, details of the 
materials and methods, manuscript integrity, manuscript title appropriateness, logical 
organization of the Introduction, Results and Discussion sections, and image features. 
After authors confirm the revisions made during the professional editing process, the 
companies listed above should provide authors with an official manuscript language 
editing certificate, through which the company guarantees that the language of the 
manuscript has reached grade A. 
 
2.7 Processing of the revised manuscript by the science editor. Based on the worklist, 
the science editor checks whether the authors have revised the manuscript according to 
the reviewers’ comments and whether the non-native English speaking authors have 
submitted a language editing certificate. If all the documents have met the requirements 
of academic publishing, they will be sent to the editorial director for review. 
 
2.8 Review of the revised manuscript by the editorial director. The editorial director 
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will review the manuscript and all the related documents. If all the documents have met 
the requirements of academic publishing, the manuscript will be sent to the journal’s 
editor-in-chief for further evaluation of the academic and language qualities. 
 
2.9 Acceptance of the revised manuscript by the journal’s editor-in-chief. The journal’s 
editor-in-chief will evaluate the academic and language quality of the manuscript. Based 
on whether authors have revised the manuscript according to the reviewers’ comments 
and whether the language of the manuscript has met the requirement of academic 
publishing, the journal’s editor-in-chief will decide whether the manuscript should be 
accepted, further revised, or rejected. The manuscripts that the journal’s editor-in-chief 
recommends for acceptance will be sent to the company’s editor-in-chief for further 
review and approval of the acceptance. 
 
2.10 Approval of the manuscript’s acceptance by the company’s editor-in-chief. The 
company’s editor-in-chief performs a final evaluation of the manuscript’s editing and 
publishing qualities. Based on comments of the reviewers’ and the journal’s editor-in-
chief, and whether the language editing certificate and the documents regarding 
academic rules and norms have met the requirements of academic publishing, the 
company’s editor-in-chief will make the final decision for whether the manuscript will 
be accepted, further revised or rejected. The accepted manuscript will then enter into the 
production process, and a formal letter of acceptance will be issued to the authors. 
    For manuscripts submitted by non-native speakers of English, we take special 
measures to control the quality of the manuscript’s language. For example, Chinese 
authors must provide a language editing certificate to verify that the language of their 
manuscript has reached grade A before the manuscript is finally published. In addition, 
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the language of the manuscript must also pass a proofreading test conducted by a 
language editor who has been designated at the discretion of the editorial office. If the 
certificate is issued by a native English editor, we will arrange for a language editor 
whose native language is Chinese to proofread the manuscript. If the certificate is issued 
by a non-native English editor, we will arrange for a language editor whose native 
language is English to proofread the manuscript. Because the culture and language 
habits of each country are different, such cross-cultural proofreading can ensure the 
academic and language quality of each manuscript submitted by non-native speakers of 
English. 
 
3 STEPS TO SUBMIT MANUSCRIPTS 
Step 1: Create an author’s user account by registering your personal information in the 
Member Login System (http://www.wjgnet.com/esps/Login.aspx?RedirectType=1). A 
valid email address is required for contact with the editorial team regarding submission 
and review activities. If your email address has been registered before, please click the 
“Forgotten your password” link to retrieve your password. Then, enter your email 
address and password to gain access to our online manuscript submission system, the 
Express Submission and Peer-Review System. 
Step 2: Submit the first author’s email address.  
Step 3: Select the journal to which you want to submit your manuscript. 
Step 4: Submit full correspondence information for the corresponding author. 
Step 5: Academic misconduct. The corresponding author must provide an honest Yes or 
No answer to each of the questions listed below. For all questions with a ‘Yes’ response, 
the authors must make a special statement. 
1 Does your manuscript have any instances of plagiarism? 
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2 Does your manuscript have any instances of fabricated information? 
3 Does your manuscript have any instances of falsified information? 
4 Does your manuscript have inappropriate authorship? 
5 Does your manuscript represent a duplicate submission/multiple submissions? 
6 Does your manuscript represent an overlapping publication? 
7 Does your manuscript represent a salami publication? 
8 Does your manuscript have any instances of digital image manipulation? 
9 Has your manuscript been published in a journal in any other language than 
English, including your native language? 
Step 6: Academic rules and norms. Authors, editors and publishers all have ethical 
obligations with regard to the publication of research results. In accordance with these 
academic rules and norms, the corresponding author must provide an honest Yes or No 
answer to each of the questions listed below, prior to manuscript submission. For all 
questions with a ‘Yes’ response, the authors must upload a copy of the corresponding 
approval document(s)/letter(s) of confirmation and/or a copy of signed statement in 
PDF format. 
1 Does your manuscript contain the institutional review board statement in the 
main text? 
2 Does your manuscript contain the informed consent statement in the main text? 
3 Does your manuscript contain the clinical trial registration statement in the 
main text? 
4 Does your manuscript contain the institutional animal care and use committee 
statement in the main text? 
5 Does your manuscript contain the animal care and use statement in the main 
text? 
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6 Does your manuscript contain the biostatistics statement in the main text? 
7 Does your manuscript contain the data sharing statement in the main text? 
8 Does your manuscript contain the conflict-of-interest statement in the main text? 
Step 7: Select a time and reason for rapid publication; for example: online publishing, 24 
hours, 3 days, 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks, or ≥20 weeks. 
Step 8: Submit the manuscript title.  
Step 9: Submit all authors’ names. Please click the button “Add” to submit the author’s 
name. You can click “Add Another Field” to submit more authors’ names. 
Step 10: Select the manuscript source: Invited manuscript or unsolicited manuscript. 
Step 11: Select the article scope: clinical practice or basic science. 
Step 12: Select the specialty type. 
Step 13: Submit keywords. Abbreviated keywords should be avoided. 
Step 14: Submit the core tip. 
Step 15: Submit the abstract.  
Step 16: Submit the cover letter. The 1-page cover letter should include a clear 
description of your study’s objective, strengths and weaknesses, and key finding. The 
cover letter will be read by the invited peer reviewers and is used as the main deciding 
factor as to whether or not they will engage in the peer-review of your manuscript 
Step 17: If the manuscript is an invited manuscript, the ID number should be submitted. 
Step 18: Submit the funding agency and grant number. 
Step 19: Select the Manuscript type. Original article contains basic study, case control 
study, clinical trials study, observational study, prospective study, randomized clinical 
trial, randomized controlled trial, retrospective cohort study, and retrospective study. 
Step 20: Submit the academic rules and norms-related documents for any manuscript 
type’s requirement. Please click the button “Browse”, and select the document you want 
 22 
 
8226 Regency Drive, Pleasanton, CA 94588, USA 
Telephone: +1-925-223-8242      Fax: +1-925-223-8243 
E-mail: bpgoffice@wjgnet.com  http://www.wjgnet.com 
 
 
 
 
to submit, and then click the button “Upload” to submit the document.  
  The first step in the peer-review process is to assess whether the manuscript itself meets 
the basic standards for ethics in publication; the features assessed include academic 
misconduct, academic rules and norms, ethics-related statements, and efforts on the part 
of non-native speakers of English. To aid in this step, the authors must ensure that they 
have prepared and provided the following items before submitting their manuscript. 
   If the manuscript type selected is Editorial, Frontier, Diagnostic Advances, Therapeutic 
Advances, Field of Vision, Minireview, Review, Topic Highlight, or Letter to the Editor, the 
Conflict-of-interest statement has to be submitted. 
   If the manuscript type selected is Basic Study, the Institutional Review Board statement, 
Institutional Animal Care and Use Committee statement, Animal care and use statement, 
Biostatistics statement, and Conflict-of-interest statement have to be submitted. 
If the manuscript type selected is Clinical Trials Study, Prospective Study, Randomized 
Clinical Trial, or Randomized Controlled Trial, the Institutional Review Board statement, 
Clinical trial registration statement, Informed consent statement, Biostatistics statement, 
and Conflict-of-interest statement have to be submitted. 
   If the manuscript type selected is Observational Study, Retrospective Cohort Study, or 
Retrospective Study, the Institutional Review Board statement, Informed consent 
statement, Biostatistics statement, and Conflict-of-interest statement have to be 
submitted. 
   If the manuscript type selected is Evidence-Based Medicine, Systematic Review, Meta-
Analysis, or Scientometrics, the Biostatistics statement and Conflict-of-interest statement 
have to be submitted. 
   If the manuscript type selected is Case Report, the Institutional Review Board statement, 
Informed consent statement, and Conflict-of-interest statement have to be submitted. 
Step 21: Non-native English-speaking authors must submit an English language editing 
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certificate.  To ensure that the peer reviewers can give a fair and objective assessment of 
the manuscript, non-native English-speaking authors must seek out and use the services 
of a professional editing service provider, either a professional English language editing 
company or a qualified colleague (with evidenced expertise and experience in English 
language editing of scientific and medical manuscripts).  
Step 22: Submit the complete list of all publications of the corresponding author. This list 
will be verified by our science editors and peer reviewers to confirm that the 
corresponding author has not published similar paper(s). 
Step 23: Submit the original sources of the manuscript, if the manuscript has been 
published in a journal in any other language than English, including your native 
language. 
Step 24: Submit any audio, video, and supplementary material related to the manuscript. 
Step 25: Submit the full manuscript, including text, figures, and tables.  
Step 26: After all the above steps are completed, please click the “Submit” button to 
finish this submission. 
